

DMD # 85142

## **Regulation of Hepatic Long Non-coding RNAs by PXR and CAR Agonists in Mouse Liver**

Joseph L. Dempsey and Julia Yue Cui

Department of Environmental and Occupational Health Sciences, University of  
Washington, Seattle WA 98105, USA

DMD # 85142

## Running Title:

LncRNAs regulated by PXR and CAR agonists in mouse liver

## Send correspondence to:

Julia Yue Cui, PhD, DABT  
4225 Roosevelt Way NE, Suite 100  
Seattle, WA 98105  
Department of Environmental and Occupational Health Sciences  
University of Washington  
Seattle WA 98105  
Email: [juliacui@uw.edu](mailto:juliacui@uw.edu)  
Tel: 206-616-4331

## Manuscript statistics:

Text pages: 45  
Tables: 0  
Figures: 6  
References: 77  
Abstract: 297  
Introduction: 963  
Discussion: 2160

## Abbreviations:

5MeC, DNA methylation and cytosine 5th position; AhR, aryl hydrocarbon receptor; AS, anti-sense; BAM, binary alignment/map; CAR, constitutive androstane receptor; ChIP-Seq, chromatin immunoprecipitation coupled with high throughput sequencing; CYP, cytochrome P450; FPKM, fragments per kilobase of exon per million reads mapped; H3K27me3, H3 lysine 27 trimethylation; H3K4me2, H3 lysine 4 di-methylation; HISAT, Hierarchical Indexing for Spliced Alignment of Transcripts; HNF, hepatocyte nuclear factor; lncRNA, long noncoding RNA; PCG, protein-coding gene; PCN, pregnenolone-16 $\alpha$ -carbonitrile; PXR, pregnane X receptor; SAM, sequencing alignment/map; siRNA, small interfering RNA; TCPOBOP, 1, 4-bis[2-(3, 5-dichloropyridyloxy)]benzene; TSS, transcription start site; TTS, transcriptional termination site; UTR, untranslated region

DMD # 85142

## ABSTRACT

Altered expression of lncRNAs by environmental chemicals modulates the expression of xenobiotic biotransformation related genes and may serve as therapeutic targets and novel biomarkers of exposure. The pregnane X receptor (PXR/NR1I2) is a critical xenobiotic-sensing nuclear receptor that regulates the expression of many drug-processing genes, and it has similar target gene profiles and DNA binding motifs with another xenobiotic-sensing nuclear receptor, namely constitutive androstane receptor (CAR/Nr1i3). To test our hypothesis that lncRNAs are regulated by PXR in concert with protein-coding genes (PCGs) and to compare the PXR-targeted lncRNAs with CAR-targeted lncRNAs, RNA-Seq was performed from livers of adult male C57BL/6 mice treated with corn oil, the PXR agonist PCN, or the CAR agonist TCPOBOP. Among 125,680 known lncRNAs, 3,843 were expressed in liver and 193 were differentially regulated by PXR (among which 40% were also regulated by CAR). The majority of PXR- or CAR-regulated lncRNAs were mapped to the introns and 3'-UTRs of PCGs as well as intergenic regions. Combining the RNA-Seq data with a published PXR ChIP-Seq dataset (Cui et al., 2010b), we identified 774 expressed lncRNAs with direct PXR-DNA binding sites, and 26.8% of differentially expressed lncRNAs had changes in PXR-DNA binding following PCN exposure. *De novo* motif analysis identified co-localization of PXR with LRH-1, which regulates bile acid synthesis, following PCN exposure. There was limited overlap of PXR binding with an epigenetic mark for transcriptional activation (histone-H3K4-di-methylation, H3K4me2), but no overlap with

## DMD # 85142

epigenetic marks for transcriptional silencing (H3K27me3 and DNA methylation). Among differentially expressed lncRNAs, 264 were in proximity of PCGs, and the lncRNA-PCG pairs displayed a high co-regulatory pattern by PXR and CAR activation. This study was among the first to demonstrate that lncRNAs are regulated by PXR and CAR activation and that they may be important regulators of PCGs involved xenobiotic metabolism.

DMD # 85142

## INTRODUCTION

Long non-coding RNAs (lncRNAs) are functional transcripts over 200 nucleotides in length whose genes are estimated to comprise at least 62-75% of the human genome (Djebali et al., 2012; St Laurent et al., 2015). According to the ENCODE Project, lncRNAs represent approximately 80% of functional sequences in the human DNA and are the predominant non-ribosomal and non-mitochondrial RNA species in human cells (Kapranov et al., 2010; Consortium, 2012). LncRNAs transcribed proximally or distally to protein-coding genes (PCGs) can modulate a wide spectrum of biological events, including chromatin epigenetic remodeling, transcription factor assembly, alternative splicing, mRNA stability, and protein translation efficiency (Geisler and Collier, 2013; Karlsson and Baccarelli, 2016; Dempsey and Cui, 2017). Growing evidence in the literature suggests that lncRNAs are novel biomarkers and/or key contributors during physiological, pharmacological, and toxicological responses, including complex human diseases, developmental disorders, as well as xenobiotic-induced adverse outcomes (Dempsey and Cui, 2017).

Many lncRNAs are highly expressed in liver, which is a major organ for xenobiotic biotransformation and nutrient homeostasis. A stringent computational pipeline identified 15,558 lncRNAs that are expressed in mouse liver, based on an analysis of 186 mouse liver RNA-Seq datasets ranging over 30 biological conditions (Yu et al., 2017). Interestingly, Yu et al. also demonstrated greater inter-species conservations within DNA sequences and higher frequency of proximal binding by hepatic transcription factors in the liver-

## DMD # 85142

expressed lncRNA gene promoters as compared to protein-coding gene (PCG) promoters (Yu et al., 2017). The liver-enriched lncRNAs were predicted to be metabolically sensitive regulators with diverse functions in physiological homeostasis, especially energy metabolism (Yang et al., 2016). Regulation of genes involved in energy metabolism and nutrient homeostasis by lncRNAs found in the literature include gluconeogenesis (Goyal et al., 2017), cholesterol and bile acid homeostasis (Ananthanarayanan, 2016; Lan et al., 2016; Yu et al., 2017; Zhang et al., 2017), lipid metabolism (Li et al., 2015; Chen, 2016; Yang et al., 2016; Li et al., 2017; Zhao et al., 2017), and non-alcoholic fatty liver disease (Chen et al., 2017).

In addition to modulating intermediary metabolism in liver, lncRNAs are suggested to modulate hepatic xenobiotic biotransformation. For example, two lncRNAs that are transcribed from the anti-sense strands of the DNA encoding the hepatocyte nuclear factor 1 $\alpha$  (HNF1 $\alpha$ ) and HNF4 $\alpha$  are important in regulating the major drug-metabolizing cytochrome P450s (Cyps) in human liver cancer-derived HepaRG cells (Chen et al., 2018). Specifically, short hairpin RNA (shRNA) knockdown of the lncRNA gene *HNF1 $\alpha$  antisense 1 (AS-1)* decreased the mRNA expression of PXR and CAR, as well as the expression of seven major P450s (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, and CYP3A4) in hepaRG cells. In addition, small interfering RNA (siRNA) knockdown of the lncRNA gene *HNF4 $\alpha$ -AS1* increased the mRNA expression of PXR as well as the expression of six P450s (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2E1, and CYP3A4). This indicated that there is a complex

## DMD # 85142

network between transcription factors and lncRNAs that regulate the expression of P450s (Chen et al., 2018).

During postnatal liver maturation, the developmental expression patterns of various lncRNAs have been unveiled at 12 developmental ages in mice (Peng et al., 2014), and the potential role of lncRNAs in regulating the ontogenic expression of the xenobiotic-metabolizing Cyps was proposed (Ingelman-Sundberg et al., 2013). LncRNAs have also been suggested to confer drug resistance through modulating the stability and translation of mRNAs that produce proteins involved in cell survival, proliferation, and drug metabolism (Pan et al., 2015). However, very little is known regarding to what extent the hepatic lncRNAs are regulated by exposure to drugs and other xenobiotics.

Regarding xenobiotic biotransformation, in liver, the nuclear receptors pregnane X receptor (PXR/Nr1i2) and constitutive androstane receptor (CAR/Nr1i3) are major xenobiotic-sensing nuclear receptors that can be activated by a wide spectrum of therapeutic drugs, environmental toxicants, dietary factors, and endogenous chemicals (Kliewer et al., 2002; Willson and Kliewer, 2002; Moore et al., 2003; Pacyniak et al., 2007). Upon activation, PXR and CAR play critical roles in xenobiotic bio-activation and detoxification (Handschin and Meyer, 2003). In addition, recent studies have unveiled novel functions of these drug receptors in various intermediary metabolism pathways, such as lipid and glucose metabolism (Poulin-Dubois and Shultz, 1990; Wada et al., 2009; Gao and Xie, 2010; Mackowiak et al., 2018; Pu et al., 2018). Our research group and others have extensively characterized the effect of

## DMD # 85142

pharmacological activation of PXR and CAR on the regulation of various protein-coding genes, especially the drug-processing genes in liver (Cheng et al., 2005b; Maher et al., 2005; Kiyosawa et al., 2008; Pratt-Hyatt et al., 2013; Oshida et al., 2015; Cui and Klaassen, 2016).

There has been some investigation on effect of the CAR ligand 1, 4-bis[2-(3, 5-dichloropyridyloxy)]benzene (TCPOBOP) on the hepatic chromatin assembly and certain lncRNAs that contribute to liver tumor promotion (Lempiainen et al., 2013; Lodato et al., 2018). TCPOBOP differentially regulated 166 lncRNAs in liver that are produced from intragenic or anti-sense strand relative to PCGs that encode CAR-regulated drug-metabolizing enzymes, suggesting that an efficient co-regulatory mechanism may exist (Yu et al., 2017). In addition, two studies have investigated the effect of activating the xenobiotic-sensing transcription factor aryl hydrocarbon receptor (AhR) on the hepatic expression of lncRNAs (Recio et al., 2013; Grimaldi et al., 2018). However, there have been no systematic studies characterizing the effect of PXR activation on the regulation of liver-enriched lncRNAs and how PXR activation differs from CAR activation regarding lncRNA expression profiles.

Therefore, the purpose of the present study was to 1) determine the effect of pharmacological activation of PXR on the hepatic expression of lncRNAs; 2) to identify direct PXR-binding sites to the lncRNA gene loci and associated epigenetic signatures under basal and PXR activated conditions; 3) to compare the similarities and differences between PXR and CAR targeted lncRNAs; and 4)



DMD # 85142

to predict the lncRNA-regulated protein-coding gene networks following PXR/CAR activation in mouse liver.

## MATERIALS AND METHODS

### **Chemicals**

Corn oil (vehicle), the mouse PXR ligand pregnenolone-16 $\alpha$ -carbonitrile (PCN;  $\geq$  97% purity; CAS Number 1434-54-4), and the mouse CAR ligand 1,4-*bis*-[2-(3,5-dichloropyridyloxy)]benzene,3,3',5,5'-tetrachloro-1,4-*bis*(pyridyloxy)benzene (TCPOBOP;  $\geq$  98% purity; CAS Number 76150-91-9) were purchased from Sigma-Aldrich (St. Louis, MO).

### **Animals and procedures**

As described previously (Cui and Klaassen, 2016), 12-week-old adult male C57BL/6 wild-type mice were purchased from Charles River Laboratories (Wilmington, MA) and were housed in an Association for Assessment and Accreditation of Laboratory Animal Care International-accredited facility (Animal Care and Use Program number 2011-1969) at the University of Kansas Medical Center (KUMC) with *ad libitum* access to the Laboratory Rodent Chow 8604 (Harlan, Madison, WI) and drinking water. The housing conditions were temperature- and humidity-controlled with a 14-hour light and 10-hour dark cycle in a temperature- and humidity-controlled environment. Mice were acclimated for at least one week within the animal facilities prior to experiments. Mice were administered PCN (200 mg/kg, i.p.), TCPOBOP (3 mg/kg, i.p.), or vehicle (corn

DMD # 85142

oil, 5 ml/kg, i.p.) once daily for four consecutive days (n=5 per group). Twenty-four hours after the final dose, livers were collected, immediately frozen in liquid nitrogen, and stored in a -80 °C freezer. All animal experiments were approved by the IACUC at KUMC.

### ***RNA isolation***

Total RNA was isolated from mouse liver using RNA-Bee reagent (Tel-Test Inc., Friendswood, TX) per the manufacturer's protocol and quantified using a Nanodrop 1000 Spectrophotometer (Thermo Scientific, Wilmington, DE). RNA integrity was confirmed using gel electrophoresis and a dual Agilent 2100 Bioanalyzer (Agilent Technologies Inc., Santa Clara, CA). RNA samples used for cDNA library construction and RNA sequencing had RNA integrity (RIN) values between 7.0 and 10.0. .

### ***cDNA library construction and RNA-Seq data analysis***

The cDNA library preparation from poly-A selection was performed in the KUMC Genome Sequencing Facility, as described previously (Cui and Klaassen, 2016). Samples for sequencing were randomly selected (n=3 per group) from all biological replicates (n=5) for all studies. Sequencing was performed on an Illumina HiSeq2000 sequencer using 100 bp paired-end multiplexing strategy. FASTQ files and analyzed data are available at NCBI GEO database (GSE104734), and data were re-analyzed for the present study. Briefly, FASTQ files containing paired-end sequence reads were mapped to the mouse reference genome (GRCm38/mm10) using HISAT2 (Hierarchical Indexing for Spliced

## DMD # 85142

Alignment of Transcripts) (version 2.0.5). The output SAM (sequencing alignment/map) files were converted to BAM (binary alignment/map) files and sorted using SAMtools (version 1.3.1). The transcript abundance for lncRNAs and PCGs was estimated by Cufflinks (version 2.2.1) using the NONCODE 2016 lncRNA and UCSC mm10 PCG reference databases, respectively. The mRNA abundance was expressed as fragments per kilobase of exon per million reads mapped (FPKM). lncRNAs and PCGs with an average FPKM above 1 in at least one sample were considered expressed. Differential analysis was performed using Cuffdiff, and transcripts with  $p < 0.05$  were considered differentially regulated by chemical exposure. Data were expressed as mean FPKM  $\pm$  S.E., and asterisks (\*) represent statistically significant differences between vehicle and chemical exposure. Two-way hierarchical clustering dendrograms of differentially regulated lncRNAs were generated using the native function of R.

### ***Genomic annotation of lncRNAs and proximal lncRNA-PCG pair identification.***

To annotate and visualize the genomic location of lncRNAs relative to the closest PCGs, the web-based tool peak annotation and visualization (PAVIS, <https://manticore.niehs.nih.gov/pavis2/>) was used to identify lncRNAs proximal to PCGs, including 5 kb upstream of the transcription start site (TSS), intronic, exonic, 5'-untranslated region (UTR), 3'-UTR, and up to 1 kb downstream of the transcriptional termination site (TTS). A lncRNA and PCG are considered paired if 1) the lncRNA overlaps with or is within 5 kb upstream of the TSS or 1 kb

DMD # 85142

downstream of TTS of any PCG and 2) both the lncRNA and the proximal PCG were differentially expressed between vehicle and chemical exposed mice (FPKM > 1 at least one sample and  $p < 0.05$ ). Gene structure and relative genomic location of the lncRNA-PCG pairs were visualized using Integrated Genome Viewer (Broad Institute, Cambridge, MA). Pathways that are associated with PCGs paired with lncRNAs were shown using Ingenuity Pathway Analysis (IPA) software.

***PXR ChIP-Seq and motif analysis for PXR-DNA binding near lncRNA gene loci.***

The PXR ChIP-Seq was performed in livers of corn oil or PCN exposed adult male C57BL/6 mice as described previously (Cui et al., 2010b), and data were re-analyzed for the present study. The chromosome coordinates of positive PXR DNA binding peaks in either corn oil or PCN exposed conditions were retrieved. The chromosome coordinates for the enrichment locations were adjusted to match mm10 using Galaxy to be consistent with the reference genome used in the RNA-Seq dataset. The lncRNA genes differentially regulated by PCN were examined for positive enrichment of PXR-DNA binding peaks within 10 kb upstream of the TSS and 10 kb downstream of the TTS. The Motif analysis of PXR binding sites near lncRNA gene loci was performed using Homer (findMotifsGenome.pl). DNA sequences associated with the PXR-DNA binding sites were retrieved using the mouse mm10 genome. The size of the analyzed DNA regions was set as 200 bp, and the motif lengths for *de novo* motif search were set at 8, 10, and 12bp.

DMD # 85142

### ***Epigenetic marks near PXR-regulated lncRNAs.***

The positive enrichment of the active gene transcription mark histone H3 lysine 4 di-methylation (H3K4me2) as well as the gene silencing marks H3K27me3 and DNA methylation (5MeC) on chromosomes 5, 12, and 15 in livers of adult C57BL/6 male mice was determined by ChIP-on-chip as described before (Cui et al., 2009; Li et al., 2009; Choudhuri et al., 2010; Cui et al., 2010a). The chromosome coordinates for the epigenetic mark locations that were originally generated were lifted-over to mm10 using Galaxy to be consistent with the reference genomes used in the PXR ChIP-Seq and RNA-Seq datasets. The potential co-localizations of PXR and the three epigenetic marks within  $\pm 10$  kb of the lncRNA gene loci were determined.

## **RESULTS**

### ***Overall comparison of PCN- and TCPOBOP-regulated liver-expressed lncRNAs***

As shown in Figure 1, the majority (>120,000) of the lncRNAs were below the detection limit in mouse livers under any exposure condition, whereas approximately 4,000 lncRNAs were expressed (average FPKM > 1 in at least one group). Among these liver-expressed lncRNAs, most of them showed stable expression and were not altered following PCN (96%) or TCPOBOP (86%) exposure. PCN up-regulated approximately 2% and down-regulated 2% of the liver-expressed lncRNAs, whereas TCPOBOP up-regulated 7% and down-regulated approximately 7% of the liver-expressed lncRNAs.

DMD # 85142

As shown in Figure 2A, TCPOBOP in general had a more prominent effect than PCN in differentially regulating the liver expressed lncRNAs in that 193 lncRNAs were altered by PCN exposure as compared to 625 that were altered by TCPOBOP exposure. There were 81 lncRNAs that were commonly regulated by both PCN and TCPOBOP, suggesting that PXR and CAR have unique lncRNA gene targets in liver. A two-way hierarchical clustering dendrogram showed that biological replicates from the same exposure groups clustered together for the lncRNA gene expression (Figure 2B) and confirmed that TCPOBOP had a more profound effect in both up- and down-regulation of lncRNAs. This may be due to TCPOBOP being a highly potent activator of CAR, whereas the potency of PCN is less towards PXR activation.

***Genomic annotation of PCN- and TCPOBOP-regulated liver-expressed lncRNAs relative to PCGs and predicted gene networks***

As a first step to predict the function of lncRNAs with regards to influencing the transcriptional output of PCGs, the genomic locations of PCN- and TCPOBOP-regulated lncRNAs relative to the PCGs were determined using PAVIS, and the lncRNA-PCG gene pairs were defined if they met all of the following criteria: 1) the lncRNA gene overlaps with or is within 5 kb upstream of TSS or 1 kb downstream of TTS of any PCG and 2) both the lncRNA and the proximal PCG were differentially expressed by PCN or TCPOBOP exposure (average FPKM > 1 and  $p < 0.05$ ). These criteria were set based on the assumption that although exceptions may exist, lncRNAs produced locally around the neighboring PCGs have a more spatial advantage in influencing the

## DMD # 85142

transcriptional output of these PCGs as compared to lncRNAs produced in distal regions (Orom et al., 2010; Kim et al., 2012; Villegas and Zaphiropoulos, 2015; Engreitz et al., 2016; Chen et al., 2018).

As shown in Figure 3A and Supplemental Table 1, following PCN exposure, 141 (73.1%) of 193 lncRNAs differentially regulated by PCN paired with distinct PCGs. The remaining 52 (26.9%) were produced from the intergenic regions and did not pair with any PCGs. As shown in Figure 3B, among the lncRNAs that paired with PCGs, the majority of them were produced from the intronic regions of PCGs (43%), followed by the 3'-untranslated regions (3'-UTRs) (14.5%), exonic regions (6.7%), downstream of TTS (5.2%), and upstream of TSS (3.6%). There were no lncRNAs that were co-differentially regulated by PCN and were produced within the 5'-UTR of PCGs that were differentially regulated by PCN. The PCGs that paired with lncRNAs formed distinct signaling networks including lipid metabolism, molecular transport, and small molecular biochemistry centering around ERK1/2, which is a MAP kinase that catalyzes the phosphorylation of many cytoplasmic and nuclear substrates (Supplemental Figure 1), as well as cellular growth and proliferation (Supplemental Figure 2). For example, HDL as well as its regulator serum amyloid A1 (SAA1) was down-regulated, whereas AMPK, which activates glucose and fatty acid uptake and oxidation, was up-regulated.

Following TCPOBOP exposure, additional lncRNA-PCG pairs were discovered. As shown in Figure 3C and Supplemental Table 2, 359 (73%) lncRNAs were paired with PCGs, whereas 134 were not paired (27.1%). Similar

DMD # 85142

to the PCN exposure conditions, the majority of the paired lncRNAs were produced from the intronic (34%) and 3'-UTR (21.5%) of the PCGs, followed by downstream (6.4%), upstream (6.1%), and exonic (5.3%) regions, whereas the mapping to 5'-UTR was minimal (0.2%) (Figure 3D). Also similar to PCN exposure, the PCGs that paired with lncRNAs following TCPOBOP exposure were also important for lipid metabolism and molecular transport (Supplemental Figure 3). For example, Apolipoprotein A4 (ApoA4), which is a lipid transporter, was up-regulated, whereas SAA1, which plays an important role in HDL metabolism and cholesterol homeostasis, was down-regulated (Supplemental Figure 3). In addition, the carcinogenesis network was enriched in TCPOBOP-regulated PCGs that paired with lncRNAs (Supplemental Figure 4).

### ***PXR-DNA binding to PCN-regulated hepatic lncRNAs and motif analysis***

As shown in Figure 4, both the total numbers of PXR-DNA binding sites and the cumulative PXR-DNA binding fold enrichment near the lncRNA gene loci ( $\pm 10$  kb) increased following PCN exposure. Approximately 70% of the differentially regulated lncRNAs had no PXR binding. Interestingly, among the direct PXR-targeted lncRNA genes, both the up-regulated and the down-regulated lncRNAs had increased PXR-DNA binding. This indicates that PXR has dual functions in the transcription of these lncRNAs—cis-activation and cis-suppression (Figure 4C and 4D)—likely due to a functional switch of other transcription factors that co-localize with PXR at these sites. To address this, *de novo* motif analysis was performed in lncRNA gene-associated PXR-DNA binding peaks in corn oil and PCN exposed conditions independently (Figure 4E).



DMD # 85142

Interestingly, in control conditions, HNNRNPA2B1 and RAR $\alpha$  were significantly enriched in PXR-DNA binding sites of the lncRNA genes, whereas Nr5a2/LRH-1 was enriched by PCN. The molecular switches of these transcription factors may alter the fate of transcriptional output of PXR-targeted lncRNA genes. Other transcription factors associated with known DNA binding motifs within the PXR-DNA binding intervals around the differentially regulated lncRNA gene loci by PCN are shown in Supplemental Figure 5A.

***Determining the potential co-localization of epigenetic factors and PXR near lncRNA gene loci.***

Distinct PCN exposure associated permissive and repressive epigenetic marks have previously been identified on mouse chromosomes 5, 12, and 15 [see Materials and Methods]. In a preliminary investigation into the role of epigenetic marks and PXR binding on lncRNA expression, we searched for co-localization of PXR-DNA binding, specific epigenetic marks (H3K4me2, H3K27me3, and 5MeC) near lncRNA loci on the same chromosomes. The majority of the lncRNAs associated with these epigenetic marks or PXR were not expressed or not detected on the three chromosomes, likely due to the presence of other suppressive marks that were not investigated in the present study, or were not detected due to the method of RNA selection in the cDNA library preparation procedure (i.e. only poly-A tailed lncRNAs were captured) (Supplemental Table 3). Among the liver-expressed lncRNAs on these three chromosomes, the majority of stably expressed lncRNAs had positive enrichment of the active chromatin epigenetic mark H3K4me2 and PXR. The overlap

## DMD # 85142

between H3K4me2 and PXR was also the most in the stably expressed lncRNA gene category. This indicates that H3K4me2 and PXR may act in concert to maintain the constitutive expression of liver-enriched lncRNAs. Interestingly, DNA methylation (5MeC), commonly thought to silence gene expression, was another epigenetic mark that co-localized with stably expressed lncRNA gene loci and overlapped a moderately with PXR binding sites. Paradoxically, although 5MeC is considered a gene silencing mark, our observation is consistent with the more recent literature report that many actively transcribed gene bodies are marked with 5MeC. This correlates with transcriptional activity rather than repression, that the basal function of gene body methylation facilitates the establishment of their constitutive expression, and that cytosine-specific methylation may regulate gene expression (Coleman-Derr and Zilberman, 2012; Vyhldal et al., 2016). Following PXR activation, a moderate number of PCN-regulated lncRNAs (either up- or down-regulated) had positive enrichment of H3K4me2, and most of these lncRNAs had direct PXR-DNA binding sites. In contrast, almost none of the PCN-regulated lncRNAs had positive enrichment of H3K27me3 or 5MeC, and there was also no overlap between these epigenetic marks and PXR at these lncRNA gene loci (Supplemental Table 3).

Two examples of lncRNAs that had co-localization of PXR and H3K4me2 are shown in Figure 5A (a lncRNA that paired with a PCG encoding P450 reductase [Por] that is important for cytochrome P450-mediated hepatic drug metabolism) and Figure 5B (an intergenic lncRNA) with the gene annotation

DMD # 85142

shown in Supplemental Figure 6. As shown in Figure 5A, the lncRNA NONMMUG034025.2 and the neighboring PCG Por were co-up-regulated by PCN, and this was associated with increased PXR-DNA binding fold-enrichment around the lncRNA-PGC loci. In addition, this region was marked with the active gene transcription mark H3K4me2, but not H3K27me3 or 5MeC. As shown in Figure 5B, the PCN-mediated up-regulation of the lncRNA NONMMUG014541.1 was also positively associated with increased PXR-DNA binding and positive enrichment of H3K4me2, but was independent of PCGs.

***Confirmation of the literature-reported CAR-targeted lncRNAs in liver following TCPOBOP exposure and comparison with the effect of PCN exposure***

Consistent with the recently published study regarding the effect of the CAR ligand TCPOBOP on the hepatic lncRNA gene expression (Lodato et al., 2018), the present study confirmed the TCPOBOP-mediated increase in 6 lncRNAs (NONMMUG002974.2, NONMMUG017205.2, NONMMUG020358.2, NONMMUG021206.2, NONMMUG026099.2, and NONMMUG036870.2) (Figure 6A), as well as the TCPOBOP-mediated decrease in 5 lncRNAs (NONMMUG005073.2, NONMMUG009893.2, NONMMUG015071.2, NONMMUG028068.2, and NONMMUG041315.2) (Figure 6B). In comparison, at the given dose, the PXR ligand PCN up-regulated 3 of the same lncRNAs (NONMMUG021206.2, NONMMUG026099.2, and NONMMUG036870.2) as TCPOBOP, albeit to a lesser extent. PCN had only minimal effects on the other TCPOBOP up-regulated lncRNAs.

DMD # 85142

## DISCUSSION

The key findings of the present study are 1) at the given doses for the nuclear receptor agonists, CAR activation affects the expression of more lncRNAs than PXR activation in liver, and both commonly and uniquely regulated lncRNAs are observed for the two receptors; 2) the majority of the differentially regulated lncRNAs are present in introns, intergenic, and 3'-UTRs relative to PCGs; 3) for both receptors, the top differentially regulated PCGs paired with lncRNAs are involved in lipid metabolism and molecular transport, highlighting the potential importance of lncRNAs in fine-tuning this signaling pathway in liver; 4) increased PXR-binding by PCN exposure may lead to either trans-activation or trans-suppression of direct lncRNA targets, and motif analysis suggests that this context-specific duality may be due to a molecular switch of co-localized transcription factors; 5) the epigenetic activation mark H3K4me2 may facilitate the PXR-recruitment to the genomic regions proximal to lncRNA gene loci for activation of gene transcription.

One technical limitation of this study was the inability to detect non-polyadenylated lncRNAs, which may also be important for liver functions, due to the use of poly-A tail selection in RNA-Seq library construction. This likely explains why a previous study identified more liver-enriched lncRNAs than the present study in mice (Figure 1) (Yu et al., 2017). It has been shown that the non-polyadenylated lncRNAs are generally expressed at lower levels than the non-polyadenylated mRNAs and are prevalent in the nucleus, suggesting that they may be involved in the transcriptional regulation of target genes (Cheng et

## DMD # 85142

al., 2005a; Furuno et al., 2006). At this time, the ratio between polyadenylated lncRNAs and non-polyadenylated lncRNAs in liver is not known and most of the well characterized lncRNAs are produced using the same machinery as the PCGs (i.e. transcribed by RNA Pol-II, polyadenylated, and spliced) (Kung et al., 2013). Future studies using whole transcriptome analysis could use ribosomal depletion as an alternative library construction option, although the trade-off appears to be lower signal per transcript at the same read depth.

An experimental limitation of the present study is the lack of validations of the findings using PXR and CAR knockout mice. Using these knockout mice would demonstrate the extent which the regulation of lncRNAs are dependent on PXR and CAR under basal conditions. Previously, one study examined the species differences in gene regulation using human CAR transgenic mice as well as CAR-null mice (Cheng et al., 2017). This study showed that expression of Cyp3a11 and Cyp2b10 was up-regulated by TCPOBOP only in livers of WT mice but not in CAR-null mice. In a separate study,  $\alpha$ -tocopherol was shown to be a PXR activator using wild-type and PXR-null mice. PXR-null compared to wild-type mice did not differ greatly in the regulated gene expression of the major P450s (Johnson et al., 2013). The purpose of the current study is to investigate those lncRNAs that are regulated by the pharmacological activation of PXR or CAR (similar to a toxicological response) as a first step. In future directions it will be important to determine the necessity of the nuclear receptors in modulating the constitutive lncRNA gene expression using knockout mice.

## DMD # 85142

Another interesting finding is that the majority of the differentially regulated lncRNAs are produced within the intronic region of the PCGs (43%), followed by the intergenic regions (26.9%) and 3'-UTRs (14.5%) (Fig. 3B). Because only the mature mRNAs that are poly-A tailed are enriched, the intronic transcripts should be separate lncRNA fragments instead of nascent mRNA transcripts. This suggests that the mammalian transcription machinery is highly efficient in that both lncRNAs and PCGs may share the same transcription machinery due to the relative genomic distributions. Intronic lncRNAs are known to initiate their transcription inside introns of PCGs in either direction and terminate without overlapping exons (Rinn and Chang, 2012). Little is known regarding the specific functions of intronic lncRNAs, although their potential involvement in cancer has been suggested (Tahira et al., 2011). Intergenic lncRNAs are encoded completely within intergenic regions between PCG loci and have been suggested to be more stable than intronic lncRNAs (Rinn and Chang, 2012). The differential regulation of intergenic lncRNAs by PXR and CAR ligands indicates the importance of PXR and CAR genomic binding to the intergenic regions. Indeed, we have previously demonstrated that approximately 30% of PXR-genomic DNA binding are present in the intergenic regions (Cui et al., 2010b). CAR ChIP-Seq experiments are challenging due to lack of a good antibody targeting endogenous CAR protein, although one could overcome this technical challenge using an adenovirus-based system to direct the expression of YFP-CAR fusion constructs in transgenic mice (Niu et al., 2018). However, it seems reasonable to speculate that a substantial number of differentially regulated

## DMD # 85142

intergenic lncRNAs by TCPOBOP may be a result of direct CAR-binding to the intergenic regions. Last, lncRNAs produced from the 3'-UTR regions relative to PCGs may be important in protecting the mRNAs from miRNA-mediated degradation and/or inhibition of protein synthesis (Karapetyan et al., 2013; Dempsey and Cui, 2017). Although lncRNAs produced in distal regions may migrate to the 3'-UTRs of PCGs and perform similar functions, the local production of lncRNAs may have a special advantage in this process.

Regarding the potency of the two nuclear receptors, at the given dose, CAR activation by TCPOBOP differentially regulated more lncRNAs in liver than did PXR activation by PCN (Figure 1). Similarly, as we observed before, CAR activation also differentially regulated more PCGs than PXR activation (Cui and Klaassen, 2016). Therefore, it appears that TCPOBOP-mediated CAR activation is a highly potent stressor leading to an overall greater change in the mouse transcriptome. Among all of the differentially regulated PCGs that paired with lncRNAs, two pathways appeared to be affected the most by PXR and CAR activation, namely lipid metabolism (Figures 3C and 4C) and cell proliferation/cancer (Supplemental Figures 1 and 2). Both nuclear receptors and certain lncRNAs have been implicated in these two pathways independently (Mo et al., 2016; Schmitt and Chang, 2016; Kong and Guo, 2018), whereas the present study is among the first to show that the biological outcomes (changes in lipid metabolism and cell proliferation status) mediated by PXR/CAR may be co-regulated by lncRNAs. The PXR-mediated change in the lipid metabolism pathway is further supported by the motif analysis in that the PXR-targeted ChIP

## DMD # 85142

DNA from PCN-treated mouse livers had enrichment in the LRH-1 DNA binding motifs (Figure 4E). LRH-1 is an important orphan nuclear receptor that regulates cholesterol, bile acid, and steroid hormone synthesis (Lee et al., 2008). The PXR activation by PCN has also been shown to be important for regulating bile acid synthesis (Staudinger et al., 2001). Under basal conditions, there was no enrichment in LRH-1 DNA binding motifs; instead, the DNA-binding motifs for hnRNP2B1, which is involved in alternative splicing of pre-mRNAs, as well as RAR $\alpha$ , which is a receptor for retinoic acid, were enriched (Fig. 5E).

Traditionally, PXR is considered a transcriptional activator for various drug metabolizing enzymes and efflux transporters. However, recent studies using ChIP-Seq and microarrays have suggested that increased PXR binding may result in either trans-activation or trans-suppression of *bona fide* PXR-targeted protein coding genes (Cui et al., 2010). The present study adds to the existing literature showing that the PXR-targeted lncRNA genes can also be further divided into inducible vs. suppressive gene batteries upon increased PXR binding. We propose two potential mechanisms for this phenomenon: 1) the co-regulators that interact with PXR may ultimately determine the fate of PXR-target gene transcription. There is evidence in the literature showing that human PXR may interact with either a co-activator (e.g. SRC-1) or a co-repressor (e.g. SMRT or NCoR) (Navaratnarajah et al., 2012). Human PXR activity is repressed by the co-repressor silencing mediator of retinoid and thyroid hormone receptors (SMRT) (Johnson et al., 2006). 2) Another possibility is that PXR may compete with other trans-activators that are more important in the transcription of the



## DMD # 85142

target genes. Previous studies showed that PXR activation inhibits cAMP responsive element binding protein (CREB) and subsequently down-regulates the expression of rate-limiting enzymes for glucose homeostasis, such as glucose-6-phosphatase catalytic subunit (G6Pase) and phosphoenolpyruvate carboxykinase 1 (PEPCK1) (Kodama et al., 2007; Oh et al., 2013). In the present study, *in silico* analysis suggests that pharmacological activation of PXR is associated with increased nuclear occupancy of LRH-1 but decreased nuclear occupancy of RAR $\alpha$  (Fig. 4E). This molecular switch may also contribute to the transcriptional silencing of a subset of PXR-targeted lncRNA genes. Additional studies using GST pull down assays as well as overlay between PXR cistrome and ChIP-Seq data of other transcription factors will verify our hypotheses.

Regarding the human relevance, it is known that both PXR and CAR both have species differences between mice and humans, especially their contribution in regulating cell proliferation (Kong and Guo, 2018; Niu et al., 2018). However, the regulation of lncRNAs may be more conserved between the two species, because it has been shown that lncRNA promoters are more conserved than lncRNA exons and almost as conserved as those of PCGs (Carninci et al., 2005; Guttman et al., 2009). In addition, there are greater species conservations and higher frequency of proximal binding by hepatic transcription factors in the liver-enriched lncRNA gene promoters than PCG promoters (Yu et al., 2017). Therefore, it is reasonable to speculate that similar regulatory patterns of the lncRNAs may also be present in human livers following PXR and CAR activation.

## DMD # 85142

The present study unveiled PCG-lncRNA pairs based on the positive associations of the neighboring PCG and lncRNAs following chemical exposure. Further mechanistic investigations are needed using lncRNA knockdown approach to validate the dependency of lncRNAs in the transcriptional/translational output of the paired PCGs. In humans, a recent study demonstrated that knocking down the neighboring lncRNAs produced from the antisense strand of the transcription factors HNF1 $\alpha$  and HNF4 $\alpha$  affected the expression of P450s in HepaRG cells (Chen et al., 2018). These observations have demonstrated the critical role of lncRNAs may play in modulating the PCG expression.

The rationale for the selection of H3K4me2, H3K27me3, and 5MeC over other epigenetic marks was that these marks were shown to associate with the regulation of important drug-processing genes in liver, as well as the focus of the present study on xenobiotic-sensing nuclear receptors (PXR and CAR). For example, the age-specific enrichment in H3K4me2 around the *Cyp3a* gene loci positively associates with the age-specific expression of the *Cyp3a* gene isoforms in mouse liver (Li et al., 2009). In addition, adult-specific enrichment of H3K4me2 positively associated with the adult-specific mRNA expression of other drug-processing genes including *glutathione S-transferase zeta 1 (Gstz1)* (Cui et al., 2010a), *UDP glucuronosyltransferase 2 and 3 (Ugt2 and Ugt3)* (Choudhuri et al., 2010), as well as *Ahr* gene locus (Cui et al., 2009). Conversely, the presence of H3K27me3 was associated with the down-regulation of CYP1A2 mRNA in human embryonic stem cell-derived hepatocytes (hESC-Hep) and primary

## DMD # 85142

human hepatocytes (Park et al., 2015). Regarding 5MeC, an investigation of DNA methylation in human liver samples demonstrated variable CpG hypermethylation of the *CYP3A4* promoter region in adults, as well as in other CCAAT-enhancer-binding proteins (C/EBP) and HNF4 $\alpha$  binding sites (Kacevska et al., 2012), indicating DNA methylation contributes to the regulation of *CYP3A4* expression and the subsequent modifications in xenobiotic metabolism. It has also been suggested that methylation of gene bodies can serve as a novel therapeutic target for cancer treatment (Yang et al., 2014). Because many drug-processing genes are known PXR and CAR targets, and the present study identified that many lncRNAs are also regulated by these drug receptors, the primary goal of the present study was to determine the interactions between these liver genes and the enrichment of these three epigenetic marks related to xenobiotic biotransformation. Many other epigenetic marks have been identified in the literature (Tan et al., 2011; Rivera and Ren, 2013), and it is important to investigate the involvement of these other marks in PXR- and CAR-mediated regulation of PCGs and lncRNAs in future studies.

Previously, it was demonstrated that the majority of lncRNAs share similar epigenetic marks at the promoter regions, such as H3K4me3 and RNA Pol-II binding sites as PCGs. However, a certain fraction of lncRNAs display a high prevalence of H3K4me1, which marks the enhancer region (Kashi et al., 2016). The present study adds to the evidence showing that a subset of mouse chromosomes (5, 12, and 15), H3K4me2, which marks the enhancers and actively transcribed gene bodies, is co-localized with PXR-DNA binding near the

DMD # 85142

PCG-lncRNA gene loci, leading to active gene transcription. H3K4me2 may provide a permissive chromatin environment for PXR-binding and the subsequent gene transcription, and may serve as an important mechanism for the co-expression of the PCG-lncRNA pairs.

Taken together, the present study is among the first to systemically compare the PXR- and CAR-targeted lncRNA profiles in liver, and has provided novel insights into the molecular mechanisms underlying the lncRNA gene transcriptional regulation and potential biological outcomes in liver, and lay the foundation for further decoding the mechanism of the regulation of the gene transcription and the lncRNA-PCG networks *in vivo*.

## ACKNOWLEDGEMENTS

The authors would like to thank Dr. Curtis Klaassen and members of the Cui Laboratory in revising the manuscript, as well as Drs. Xiao-bo Zhong and Hong Lu for their effort and collaboration in the previously published work from the ChIP-on-chip experiments.

## AUTHORSHIP CONTRIBUTIONS

Participated in research design: Cui

Conducted experiments: Cui

Performed data analysis: Dempsey, Cui

Wrote or contributed to the writing of the manuscript: Dempsey, Cui

DMD # 85142

## REFERENCES

- Ananthanarayanan M (2016) A novel long noncoding RNA regulating cholesterol and bile acid homeostasis: A new kid on the block and a potential therapeutic target? *Hepatology* **64**:16-18.
- Carninci P Kasukawa T Katayama S Gough J Frith MC Maeda N Oyama R Ravasi T Lenhard B Wells C Kodzius R Shimokawa K Bajic VB Brenner SE Batalov S Forrest AR Zavolan M Davis MJ Wilming LG Aidinis V Allen JE Ambesi-Impiombato A Apweiler R Aturaliya RN Bailey TL Bansal M Baxter L Beisel KW Bersano T Bono H Chalk AM Chiu KP Choudhary V Christoffels A Clutterbuck DR Crowe ML Dalla E Dalrymple BP de Bono B Della Gatta G di Bernardo D Down T Engstrom P Fagiolini M Faulkner G Fletcher CF Fukushima T Furuno M Futaki S Gariboldi M Georgii-Hemming P Gingeras TR Gojobori T Green RE Gustincich S Harbers M Hayashi Y Hensch TK Hirokawa N Hill D Huminiecki L Iacono M Ikeo K Iwama A Ishikawa T Jakt M Kanapin A Katoh M Kawasawa Y Kelso J Kitamura H Kitano H Kollias G Krishnan SP Kruger A Kummerfeld SK Kurochkin IV Lareau LF Lazarevic D Lipovich L Liu J Liuni S McWilliam S Madan Babu M Madera M Marchionni L Matsuda H Matsuzawa S Miki H Mignone F Miyake S Morris K Mottagui-Tabar S Mulder N Nakano N Nakauchi H Ng P Nilsson R Nishiguchi S Nishikawa S Nori F Ohara O Okazaki Y Orlando V Pang KC Pavan WJ Pavesi G Pesole G Petrovsky N Piazza S Reed J Reid JF Ring BZ Ringwald M Rost B Ruan Y Salzberg SL Sandelin A Schneider C Schonbach C Sekiguchi K Semple CA Seno S

DMD # 85142

- Sessa L Sheng Y Shibata Y Shimada H Shimada K Silva D Sinclair B Sperling S Stupka E Sugiura K Sultana R Takenaka Y Taki K Tammoja K Tan SL Tang S Taylor MS Tegner J Teichmann SA Ueda HR van Nimwegen E Verardo R Wei CL Yagi K Yamanishi H Zabarovsky E Zhu S Zimmer A Hide W Bult C Grimmond SM Teasdale RD Liu ET Brusic V Quackenbush J Wahlestedt C Mattick JS Hume DA Kai C Sasaki D Tomaru Y Fukuda S Kanamori-Katayama M Suzuki M Aoki J Arakawa T Iida J Imamura K Itoh M Kato T Kawaji H Kawagashira N Kawashima T Kojima M Kondo S Konno H Nakano K Ninomiya N Nishio T Okada M Plessy C Shibata K Shiraki T Suzuki S Tagami M Waki K Watahiki A Okamura-Oho Y Suzuki H Kawai J Hayashizaki Y Consortium F Group RGER and Genome Science G (2005) The transcriptional landscape of the mammalian genome. *Science* **309**:1559-1563.
- Chen L, Bao Y, Piekos SC, Zhu K, Zhang L, and Zhong XB (2018) A Transcriptional Regulatory Network Containing Nuclear Receptors and Long Noncoding RNAs Controls Basal and Drug-Induced Expression of Cytochrome P450s in HepaRG Cells. *Mol Pharmacol* **94**:749-759.
- Chen Y, Huang H, Xu C, Yu C, and Li Y (2017) Long Non-Coding RNA Profiling in a Non-Alcoholic Fatty Liver Disease Rodent Model: New Insight into Pathogenesis. *Int J Mol Sci* **18**.
- Chen Z (2016) Progress and prospects of long noncoding RNAs in lipid homeostasis. *Mol Metab* **5**:164-170.

DMD # 85142

- Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, Long J, Stern D, Tammana H, Helt G, Sementchenko V, Piccolboni A, Bekiranov S, Bailey DK, Ganesh M, Ghosh S, Bell I, Gerhard DS, and Gingeras TR (2005a) Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. *Science* **308**:1149-1154.
- Cheng SL, Bammler TK, and Cui JY (2017) RNA Sequencing Reveals Age and Species Differences of Constitutive Androstane Receptor-Targeted Drug-Processing Genes in the Liver. *Drug Metab Dispos* **45**:867-882.
- Cheng X, Maher J, Dieter MZ, and Klaassen CD (2005b) Regulation of mouse organic anion-transporting polypeptides (Oatps) in liver by prototypical microsomal enzyme inducers that activate distinct transcription factor pathways. *Drug Metab Dispos* **33**:1276-1282.
- Choudhuri S, Cui Y, and Klaassen CD (2010) Molecular targets of epigenetic regulation and effectors of environmental influences. *Toxicol Appl Pharmacol* **245**:378-393.
- Coleman-Derr D and Zilberman D (2012) DNA methylation, H2A.Z, and the regulation of constitutive expression. *Cold Spring Harb Symp Quant Biol* **77**:147-154.
- Consortium EP (2012) An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**:57-74.
- Cui JY, Choudhuri S, Knight TR, and Klaassen CD (2010a) Genetic and epigenetic regulation and expression signatures of glutathione S-transferases in developing mouse liver. *Toxicol Sci* **116**:32-43.

DMD # 85142

Cui JY, Gunewardena SS, Rockwell CE, and Klaassen CD (2010b) ChIPing the cistrome of PXR in mouse liver. *Nucleic Acids Res* **38**:7943-7963.

Cui JY and Klaassen CD (2016) RNA-Seq reveals common and unique PXR- and CAR-target gene signatures in the mouse liver transcriptome. *Biochim Biophys Acta* **1859**:1198-1217.

Cui YJ, Yeager RL, Zhong XB, and Klaassen CD (2009) Ontogenic expression of hepatic Ahr mRNA is associated with histone H3K4 di-methylation during mouse liver development. *Toxicol Lett* **189**:184-190.

Dempsey JL and Cui JY (2017) Long Non-Coding RNAs: A Novel Paradigm for Toxicology. *Toxicol Sci* **155**:3-21.

Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, Xue C, Marinov GK, Khatun J, Williams BA, Zaleski C, Rozowsky J, Roder M, Kokocinski F, Abdelhamid RF, Alioto T, Antoshechkin I, Baer MT, Bar NS, Batut P, Bell K, Bell I, Chakraborty S, Chen X, Chrast J, Curado J, Derrien T, Drenkow J, Dumais E, Dumais J, Duttagupta R, Falconnet E, Fastuca M, Fejes-Toth K, Ferreira P, Foissac S, Fullwood MJ, Gao H, Gonzalez D, Gordon A, Gunawardena H, Howald C, Jha S, Johnson R, Kapranov P, King B, Kingswood C, Luo OJ, Park E, Persaud K, Preall JB, Ribeca P, Risk B, Robyr D, Sammeth M, Schaffer L, See LH, Shahab A, Skancke J, Suzuki AM, Takahashi H, Tilgner H, Trout D, Walters N, Wang H, Wrobel J, Yu Y, Ruan X, Hayashizaki Y, Harrow J, Gerstein M, Hubbard T, Reymond A, Antonarakis SE, Hannon G, Giddings MC, Ruan Y, Wold B, Carninci P,



DMD # 85142

- Guigo R, and Gingeras TR (2012) Landscape of transcription in human cells. *Nature* **489**:101-108.
- Engreitz JM, Haines JE, Perez EM, Munson G, Chen J, Kane M, McDonel PE, Guttman M, and Lander ES (2016) Local regulation of gene expression by lncRNA promoters, transcription and splicing. *Nature* **539**:452-455.
- Furuno M, Pang KC, Ninomiya N, Fukuda S, Frith MC, Bult C, Kai C, Kawai J, Carninci P, Hayashizaki Y, Mattick JS, and Suzuki H (2006) Clusters of internally primed transcripts reveal novel long noncoding RNAs. *PLoS Genet* **2**:e37.
- Gao J and Xie W (2010) Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. *Drug Metab Dispos* **38**:2091-2095.
- Geisler S and Coller J (2013) RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. *Nat Rev Mol Cell Biol* **14**:699-712.
- Goyal N, Sivadas A, Shamsudheen KV, Jayarajan R, Verma A, Sivasubbu S, Scaria V, and Datta M (2017) RNA sequencing of db/db mice liver identifies lncRNA H19 as a key regulator of gluconeogenesis and hepatic glucose output. *Sci Rep* **7**:8312.
- Grimaldi G, Rajendra S, and Matthews J (2018) The aryl hydrocarbon receptor regulates the expression of TIPARP and its cis long non-coding RNA, TIPARP-AS1. *Biochem Biophys Res Commun* **495**:2356-2362.
- Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassady JP, Cabili MN, Jaenisch R, Mikkelsen TS, Jacks T,

DMD # 85142

- Hacohen N, Bernstein BE, Kellis M, Regev A, Rinn JL, and Lander ES (2009) Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. *Nature* **458**:223-227.
- Handschin C and Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. *Pharmacol Rev* **55**:649-673.
- Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, and Osawa Y (2013) Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. *Drug Metab Dispos* **41**:1725-1731.
- Johnson CH, Bonzo JA, Cheng J, Krausz KW, Kang DW, Luecke H, Idle JR, and Gonzalez FJ (2013) Cytochrome P450 regulation by alpha-tocopherol in Pxr-null and PXR-humanized mice. *Drug Metab Dispos* **41**:406-413.
- Kacevska M, Ivanov M, Wyss A, Kasela S, Milani L, Rane A, and Ingelman-Sundberg M (2012) DNA methylation dynamics in the hepatic CYP3A4 gene promoter. *Biochimie* **94**:2338-2344.
- Kapranov P, St Laurent G, Raz T, Ozsolak F, Reynolds CP, Sorensen PH, Reaman G, Milos P, Arceci RJ, Thompson JF, and Triche TJ (2010) The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. *BMC Biol* **8**:149.
- Karapetyan AR, Buiting C, Kuiper RA, and Coolen MW (2013) Regulatory Roles for Long ncRNA and mRNA. *Cancers (Basel)* **5**:462-490.
- Karlsson O and Baccarelli AA (2016) Environmental Health and Long Non-coding RNAs. *Curr Environ Health Rep* **3**:178-187.

DMD # 85142

- Kashi K, Henderson L, Bonetti A, and Carninci P (2016) Discovery and functional analysis of lncRNAs: Methodologies to investigate an uncharacterized transcriptome. *Biochim Biophys Acta* **1859**:3-15.
- Kim T, Xu Z, Clauder-Munster S, Steinmetz LM, and Buratowski S (2012) Set3 HDAC mediates effects of overlapping noncoding transcription on gene induction kinetics. *Cell* **150**:1158-1169.
- Kiyosawa N, Kwekel JC, Burgoon LD, Dere E, Williams KJ, Tashiro C, Chittim B, and Zacharewski TR (2008) Species-specific regulation of PXR/CAR/ER-target genes in the mouse and rat liver elicited by o, p'-DDT. *BMC Genomics* **9**:487.
- Kliwer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. *Endocr Rev* **23**:687-702.
- Kodama S, Moore R, Yamamoto Y, and Negishi M (2007) Human nuclear pregnane X receptor cross-talk with CREB to repress cAMP activation of the glucose-6-phosphatase gene. *Biochem J* **407**:373-381.
- Kong B and Guo GL (2018) Is this the time to reconsider the names for xenobiotic nuclear receptors? *Hepatology*.
- Kung JT, Colognori D, and Lee JT (2013) Long noncoding RNAs: past, present, and future. *Genetics* **193**:651-669.
- Lan X, Yan J, Ren J, Zhong B, Li J, Li Y, Liu L, Yi J, Sun Q, Yang X, Sun J, Meng L, Zhu W, Holmdahl R, Li D, and Lu S (2016) A novel long noncoding RNA

DMD # 85142

- Lnc-HC binds hnRNPA2B1 to regulate expressions of Cyp7a1 and Abca1 in hepatocytic cholesterol metabolism. *Hepatology* **64**:58-72.
- Lee YK, Schmidt DR, Cummins CL, Choi M, Peng L, Zhang Y, Goodwin B, Hammer RE, Mangelsdorf DJ, and Kliewer SA (2008) Liver receptor homolog-1 regulates bile acid homeostasis but is not essential for feedback regulation of bile acid synthesis. *Mol Endocrinol* **22**:1345-1356.
- Lempiainen H, Couttet P, Bolognani F, Muller A, Dubost V, Luisier R, Del Rio Espinola A, Vitry V, Unterberger EB, Thomson JP, Treindl F, Metzger U, Wrzodek C, Hahne F, Zollinger T, Brasa S, Kalteis M, Marcellin M, Giudicelli F, Braeuning A, Morawiec L, Zamurovic N, Langle U, Scheer N, Schubeler D, Goodman J, Chibout SD, Marlowe J, Theil D, Heard DJ, Grenet O, Zell A, Templin MF, Meehan RR, Wolf RC, Elcombe CR, Schwarz M, Moulin P, Terranova R, and Moggs JG (2013) Identification of Dlk1-Dio3 imprinted gene cluster noncoding RNAs as novel candidate biomarkers for liver tumor promotion. *Toxicol Sci* **131**:375-386.
- Li D, Cheng M, Niu Y, Chi X, Liu X, Fan J, Fan H, Chang Y, and Yang W (2017) Identification of a novel human long non-coding RNA that regulates hepatic lipid metabolism by inhibiting SREBP-1c. *Int J Biol Sci* **13**:349-357.
- Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H, Chen Y, Gucek M, Zhu J, and Cao H (2015) A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. *Cell Metab* **21**:455-467.

DMD # 85142

- Li Y, Cui Y, Hart SN, Klaassen CD, and Zhong XB (2009) Dynamic patterns of histone methylation are associated with ontogenic expression of the Cyp3a genes during mouse liver maturation. *Mol Pharmacol* **75**:1171-1179.
- Lodato NJ, Rampersaud A, and Waxman DJ (2018) Impact of CAR Agonist Ligand TCPOBOP on Mouse Liver Chromatin Accessibility. *Toxicol Sci* **164**:115-128.
- Mackowiak B, Hodge J, Stern S, and Wang H (2018) The Roles of Xenobiotic Receptors: Beyond Chemical Disposition. *Drug Metab Dispos* **46**:1361-1371.
- Maher JM, Cheng X, Slitt AL, Dieter MZ, and Klaassen CD (2005) Induction of the multidrug resistance-associated protein family of transporters by chemical activators of receptor-mediated pathways in mouse liver. *Drug Metab Dispos* **33**:956-962.
- Mo L, Shen J, Liu Q, Zhang Y, Kuang J, Pu S, Cheng S, Zou M, Jiang W, Jiang C, Qu A, and He J (2016) Irisin Is Regulated by CAR in Liver and Is a Mediator of Hepatic Glucose and Lipid Metabolism. *Mol Endocrinol* **30**:533-542.
- Moore JT, Moore LB, Maglich JM, and Kliewer SA (2003) Functional and structural comparison of PXR and CAR. *Biochim Biophys Acta* **1619**:235-238.

DMD # 85142

- Niu B, Coslo DM, Bataille AR, Albert I, Pugh BF, and Omiecinski CJ (2018) In vivo genome-wide binding interactions of mouse and human constitutive androstane receptors reveal novel gene targets. *Nucleic Acids Res.*
- Oh KJ, Han HS, Kim MJ, and Koo SH (2013) CREB and FoxO1: two transcription factors for the regulation of hepatic gluconeogenesis. *BMB Rep* **46**:567-574.
- Orom UA, Derrien T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zytnicki M, Notredame C, Huang Q, Guigo R, and Shiekhattar R (2010) Long noncoding RNAs with enhancer-like function in human cells. *Cell* **143**:46-58.
- Oshida K, Vasani N, Thomas RS, Applegate D, Gonzalez FJ, Aleksunes LM, Klaassen CD, and Corton JC (2015) Screening a mouse liver gene expression compendium identifies modulators of the aryl hydrocarbon receptor (AhR). *Toxicology* **336**:99-112.
- Pacyniak EK, Cheng X, Cunningham ML, Crofton K, Klaassen CD, and Guo GL (2007) The flame retardants, polybrominated diphenyl ethers, are pregnane X receptor activators. *Toxicol Sci* **97**:94-102.
- Pan JJ, Xie XJ, Li X, and Chen W (2015) Long Non-coding RNAs and Drug Resistance. *Asian Pac J Cancer Prev* **16**:8067-8073.
- Park HJ, Choi YJ, Kim JW, Chun HS, Im I, Yoon S, Han YM, Song CW, and Kim H (2015) Differences in the Epigenetic Regulation of Cytochrome P450 Genes between Human Embryonic Stem Cell-Derived Hepatocytes and Primary Hepatocytes. *PLoS One* **10**:e0132992.

DMD # 85142

- Peng L, Paulson A, Li H, Piekos S, He X, Li L, and Zhong XB (2014) Developmental programming of long non-coding RNAs during postnatal liver maturation in mice. *PLoS One* **9**:e114917.
- Poulin-Dubois D and Shultz TR (1990) The infant's concept of agency: the distinction between social and nonsocial objects. *J Genet Psychol* **151**:77-90.
- Pratt-Hyatt M, Lickteig AJ, and Klaassen CD (2013) Tissue distribution, ontogeny, and chemical induction of aldo-keto reductases in mice. *Drug Metab Dispos* **41**:1480-1487.
- Pu S, Wu X, Yang X, Zhang Y, Dai Y, Zhang Y, Wu X, Liu Y, Cui X, Jin H, Cao J, Li R, Cai J, Cao Q, Hu L, and Gao Y (2018) The Therapeutic Role of Xenobiotic Nuclear Receptors against Metabolic Syndrome. *Curr Drug Metab*.
- Recio L, Phillips SL, Maynor T, Waters M, Jackson AF, and Yauk CL (2013) Differential expression of long noncoding RNAs in the livers of female B6C3F1 mice exposed to the carcinogen furan. *Toxicol Sci* **135**:369-379.
- Rinn JL and Chang HY (2012) Genome regulation by long noncoding RNAs. *Annu Rev Biochem* **81**:145-166.
- Rivera CM and Ren B (2013) Mapping human epigenomes. *Cell* **155**:39-55.
- Schmitt AM and Chang HY (2016) Long Noncoding RNAs in Cancer Pathways. *Cancer Cell* **29**:452-463.
- St Laurent G, Wahlestedt C, and Kapranov P (2015) The Landscape of long noncoding RNA classification. *Trends Genet* **31**:239-251.

DMD # 85142

- Staudinger J, Liu Y, Madan A, Habeebu S, and Klaassen CD (2001) Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. *Drug Metab Dispos* **29**:1467-1472.
- Tahira AC, Kubrusly MS, Faria MF, Dazzani B, Fonseca RS, Maracaja-Coutinho V, Verjovski-Almeida S, Machado MC, and Reis EM (2011) Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. *Mol Cancer* **10**:141.
- Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, Lu Z, Ye Z, Zhu Q, Wysocka J, Ye Y, Khochbin S, Ren B, and Zhao Y (2011) Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. *Cell* **146**:1016-1028.
- Villegas VE and Zaphiropoulos PG (2015) Neighboring gene regulation by antisense long non-coding RNAs. *Int J Mol Sci* **16**:3251-3266.
- Vyhlidal CA, Bi C, Ye SQ, and Leeder JS (2016) Dynamics of Cytosine Methylation in the Proximal Promoters of CYP3A4 and CYP3A7 in Pediatric and Prenatal Livers. *Drug Metab Dispos* **44**:1020-1026.
- Wada T, Gao J, and Xie W (2009) PXR and CAR in energy metabolism. *Trends Endocrinol Metab* **20**:273-279.
- Willson TM and Kliewer SA (2002) PXR, CAR and drug metabolism. *Nat Rev Drug Discov* **1**:259-266.



DMD # 85142

Yang L, Li P, Yang W, Ruan X, Kiesewetter K, Zhu J, and Cao H (2016) Integrative Transcriptome Analyses of Metabolic Responses in Mice Define Pivotal LncRNA Metabolic Regulators. *Cell Metab* **24**:627-639.

Yang X, Han H, De Carvalho DD, Lay FD, Jones PA, and Liang G (2014) Gene body methylation can alter gene expression and is a therapeutic target in cancer. *Cancer Cell* **26**:577-590.

Yu AM, Ingelman-Sundberg M, Cherrington NJ, Aleksunes LM, Zanger UM, Xie W, Jeong H, Morgan ET, Turnbaugh PJ, Klaassen CD, Bhatt AP, Redinbo MR, Hao P, Waxman DJ, Wang L, and Zhong XB (2017) Regulation of drug metabolism and toxicity by multiple factors of genetics, epigenetics, lncRNAs, gut microbiota, and diseases: a meeting report of the 21(st) International Symposium on Microsomes and Drug Oxidations (MDO). *Acta Pharm Sin B* **7**:241-248.

Zhang L, Yang Z, Trottier J, Barbier O, and Wang L (2017) Long noncoding RNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate shp mRNA decay. *Hepatology* **65**:604-615.

Zhao Y, Wu J, Liangpunsakul S, and Wang L (2017) Long Non-coding RNA in Liver Metabolism and Disease: Current Status. *Liver Res* **1**:163-167.

DMD # 85142

## FOOTNOTE

This work was supported by National Institutes of Health (NIH) Grants [GM111381 and T32 ES007032], the University of Washington Center for Exposures, Diseases, Genomics, and Environment [P30 ES0007033], and the Murphy Endowment.

## FIGURE LEGENDS

**Figure 1.** Number of lncRNAs that were not expressed (or not detected using the poly-A selection method) and expressed in liver. A lncRNA is considered to be expressed in liver if the average FPKM is above 1 in at least one exposure groups (corn oil, PCN, or TCPOBOP). Among the liver-expressed lncRNAs, the percentages of lncRNAs that were not differentially regulated, increased, or decreased by chemical exposure were calculated and displayed as two pie charts (PCN and TCPOBOP). Differential expression was considered at  $p < 0.05$  (Cuffdiff).

**Figure 2. A.** Common and unique lncRNA targets following PCN and TCPOBOP exposure in mouse liver ( $p < 0.05$  as determined by Cuffdiff). **B.** A hierarchical clustering dendrogram showing the relative expression patterns of lncRNAs in liver in corn oil, PCN, and TCPOBOP exposed conditions. Data were standardized and are expressed as z-scores.

DMD # 85142

**Figure 3. A.** Number of lncRNAs that paired with PCGs or not paired with PCGs following PCN exposure. A lncRNA-PCG gene pair is defined as: 1) the lncRNA gene overlaps with or is within 5 kb upstream of transcription start sites (TSS) or 1 kb downstream of transcription termination sites (TTS) of any PCG and 2) both the lncRNA and the proximal PCG were differentially expressed by PCN exposure (average FPKM > 1 and  $p < 0.05$ ). **B.** Genomic annotation of PCN-regulated lncRNAs ( $p < 0.05$ ) relative to the PCGs. Data were analyzed using PAVIS. **C.** Number of lncRNAs that paired with PCGs or not paired with PCGs following TCPOBOP exposure. A lncRNA-PCG gene pair is defined as: 1) the lncRNA gene overlaps with or is within 5 kb upstream of transcription start sites (TSS) or 1 kb downstream of transcription termination sites (TTS) of any PCG and 2) both the lncRNA and the proximal PCG were differentially expressed by PCN exposure (average FPKM > 1 and  $p < 0.05$ ). **D.** Genomic annotation of TCPOBOP-regulated lncRNAs ( $p < 0.05$ ) relative to the PCGs. Data were analyzed using PAVIS.

**Figure 4. A.** Number of PXR-DNA binding sites within  $\pm 10$  kb of lncRNA gene loci in corn oil and PCN exposed conditions. **B.** Cumulatively PXR-DNA binding fold enrichment within  $\pm 10$  kb of lncRNA gene loci in corn oil and PCN exposed conditions. **C.** Percentages of induced lncRNA gene battery by PCN that had no PXR binding, no change in PXR binding, increase in PXR binding, and decreased PXR binding following PCN exposure. **D.** Percentages of decreased lncRNA gene battery by PCN that had no PXR binding, no change in PXR

DMD # 85142

binding, increase in PXR binding, and decreased PXR binding following PCN exposure. **E.** Homer *de novo* motif analysis of PXR-DNA binding intervals in corn oil and PCN exposed groups using findMotifsGenome.pl. Data were re-analyzed from the PXR ChIP-Seq dataset as described in MATERIALS AND METHODS.


**Figure 5. A.** Co-localization of PXR and H3K4me2 around the lncRNA NONMMUG034025.2 and the paired PCG Por gene loci. Integrated Genome Viewer (IGV) is a high performance visualization tool for displaying and exploring large datasets including RNA-Seq data, and can be accessed at <http://software.broadinstitute.org/software/igv/>. The genomic locations of lncRNA and PCG are visualized by IGV. Asterisks represent statistically significant differences as compared to corn oil control group ( $p < 0.05$ , Cuffdiff). FPKM: Fragments Per Kilobase of transcript per Million mapped reads, which is a unit to express RNA abundance from the RNA-Seq data. Data from RNA-Seq (corn oil and PCN exposed groups), ChIP-Seq (for PXR-DNA binding in corn oil and PCN exposed conditions), and ChIP-on-chip (for H3K4me2, H3K27me3, and 5MeC on mouse chromosomes 5, 12, and 15) were integrated as described in MATERIALS AND METHODS. **B.** Co-localization of PXR and H3K4me2 around the intergenic lncRNA NONMMUG014541.1 gene locus. The genomic location of lncRNA and PCG is visualized by IGV. Asterisks represent statistically significant differences as compared to corn oil control group ( $p < 0.05$ , Cuffdiff). Data from RNA-Seq (corn oil and PCN exposed groups), ChIP-Seq (for PXR-

DMD # 85142

DNA binding in corn oil and PCN exposed conditions), and ChIP-on-chip (for H3K4me2, H3K27me3, and 5MeC on mouse chromosomes 5, 12, and 15) were integrated as described in MATERIALS AND METHODS.

**Figure 6.** Examples of hepatic lncRNAs that were up-regulated (**A**) or down-regulated (**B**) by TCPOBOP (which are consistent with the literature report (Lodato et al., 2018). The effect of PCN on these CAR-targeted lncRNAs is also shown. Asterisks represent statistically significant differences as compared to the corn oil group ( $p < 0.05$ , Cufdiff). FPKM: Fragments Per Kilobase of transcript per Million mapped reads, which is a unit to express RNA abundance from the RNA-Seq data.

Figure 1



**Figure 2**






Figure 3










Figure 4



## E. Homer *de novo* Motif Analysis

### Corn Oil

Rank	Motif	P-value	log P-value	% of Targets	% of Background	STD(Bg STD)	Best Match/Details
1		1e-13	-3.001e+01	13.04%	0.23%	55.3bp (54.3bp)	HNRNPA2B1(RRM)/Homo_sapiens-RNCMPT00024-PBM/HughesRNA (0.746) <a href="#">More Information</a>   <a href="#">Similar Motifs Found</a>
2		1e-12	-2.801e+01	34.78%	5.97%	50.2bp (64.4bp)	RARa(NR)/K562-RARa-ChIP-Seq(Encode)/Homer(0.662) <a href="#">More Information</a>   <a href="#">Similar Motifs Found</a>


### PCN

Rank	Motif	P-value	log P-value	% of Targets	% of Background	STD(Bg STD)	Best Match/Details
1		1e-13	-3.120e+01	10.00%	0.15%	57.5bp (65.4bp)	Nr5a2/MA0505.1/Jaspar(0.811) <a href="#">More Information</a>   <a href="#">Similar Motifs Found</a>

Figure 5

DMD Fast Forward. Published on December 28, 2018 as DOI: 10.1124/dmd.118.085142  
This article has not been copyedited and formatted. The final version may differ from this version.

A



B





Figure 6



## **Supplemental Materials**

**Article title:** Regulation of Hepatic Long Non-coding RNAs by PXR and CAR Agonists in Mouse Liver

**Authors:** Joseph L. Dempsey and Julia Yue Cui

**Journal title:** Drug Metabolism and Disposition

### **Legend for supplemental materials:**

**Supplemental Figure 1.** Additional network associated with PCGs that paired with lncRNAs following PCN exposure: cellular growth and proliferation. Data were analyzed using Ingenuity Pathway Analysis (IPA). Red represents up-regulated genes; green represents down-regulated genes.

**Supplemental Figure 2.** Additional network associated with PCGs that paired with lncRNAs following TCPOBOP exposure: cancer injury. Data were analyzed using Ingenuity Pathway Analysis (IPA). Red represents up-regulated genes; green represents down-regulated genes.

**Supplemental Figure 3.** Homer known motif enrichment analysis of PXR-DNA binding intervals in corn oil and PCN exposed groups using findMotifsGenome.pl. Data were re-analyzed from the PXR ChIP-Seq dataset as described in MATERIALS AND METHODS.

**Supplemental Figure 4.** Network associated with PCGs that paired with lncRNAs following TCPOBOP exposure: cancer injury.

**Supplemental Figure 5.** Homer known motif enrichment in corn oil and PCN exposed groups.


**Supplemental Figure 6.** Examples of co-localization between PXR-binding and the epigenetic mark H3K4me2 around lncRNA gene loci.

**Supplemental Table 1.** Liver-expressed lncRNAs that were differentially regulated by PCN and their genomic distance to PCGs.


**Supplemental Table 2.** Liver-expressed lncRNAs that were differentially regulated by TCPOBOP and their genomic distance to PCGs.

**Supplemental Table 3.** Overlay between PXR-DNA binding and epigenetic marks around lncRNA gene loci on chromosomes 5, 12, and 15.


**Supplemental Figure 1. Network associated with PCGs that paired with lncRNAs following PCN exposure: lipid metabolism, molecular transport, and small molecular biochemistry**



**Supplemental Figure 2. Network associated with PCGs that paired with lncRNAs following PCN exposure: cellular growth and proliferation**




**Supplemental Figure 3. Network associated with PCGs that paired with lncRNAs following TCPOBOP exposure: lipid metabolism and molecular transport**


















































Supplemental Figure 4. Network associated with PCGs that paired with lncRNAs following TCPOBOP exposure: cancer injury



# Supplemental Figure 5. Homer Known Motif Enrichment Corn Oil


Rank	Motif	Name	P-value	log P-value	q-value (Benjamini)	# Target Sequences with Motif	% of Targets Sequences with Motif
1		COUP-TFII(NR)/K562-NR2F1-ChIP-Seq(Encode)/Homer	1e-10	-2.321e+01	0.0000	33.0	47.83%
2		RARa(NR)/K562-RARa-ChIP-Seq(Encode)/Homer	1e-9	-2.289e+01	0.0000	46.0	66.67%
3		PPARa(NR),DR1/Liver-Ppar-ChIP-Seq(GSE47954)/Homer	1e-8	-1.922e+01	0.0000	26.0	37.68%
4		COUP-TFII(NR)/Artis-Nv2f2-ChIP-Seq(GSE46497)/Homer	1e-8	-1.908e+01	0.0000	33.0	47.83%
5		CEBP(bZIP)/ThioMac-CEBPb-ChIP-Seq(GSE21512)/Homer	1e-7	-1.620e+01	0.0000	16.0	23.19%
6		THRB(NR)/Liver-NR1A2-ChIP-Seq(GSE52613)/Homer	1e-6	-1.572e+01	0.0000	50.0	72.46%
7		EAR2(NR)/K562-NR2F6-ChIP-Seq(Encode)/Homer	1e-6	-1.537e+01	0.0000	27.0	39.13%
8		PPARb(NR),DR1/3T3L1-Pparg-ChIP-Seq(GSE13511)/Homer	1e-6	-1.494e+01	0.0000	22.0	31.88%
9		RXR(NR),DR1/3T3L1-RXR-ChIP-Seq(GSE13511)/Homer	1e-6	-1.467e+01	0.0000	24.0	34.78%
10		Erra(NR)/HepG2-Erra-ChIP-Seq(GSE31477)/Homer	1e-6	-1.398e+01	0.0001	35.0	50.72%
11		THRB(NR)/HepG2-THRB-Flag-ChIP-Seq(Encode)/Homer	1e-5	-1.371e+01	0.0001	16.0	23.19%
12		HNf4a(NR),DR1/HepG2-HNF4a-ChIP-Seq(GSE25021)/Homer	1e-5	-1.363e+01	0.0001	15.0	21.74%
13		VDR(NR),DR3/GM10855-VDR-vinD-ChIP-Seq(GSE22484)/Homer	1e-4	-1.033e+01	0.0024	8.0	11.59%
14		HLF(bZIP)/HSC-HLF-Flag-ChIP-Seq(GSE69817)/Homer	1e-4	-9.959e+00	0.0033	13.0	18.84%
15		FOXA1(Forkhead)/LNCAP-FOXA1-ChIP-Seq(GSE27824)/Homer	1e-3	-9.154e+00	0.0069	17.0	24.64%
16		FoxEbox(Forkhead,bHLH)/Panc1-Foxa2-ChIP-Seq(GSE47459)/Homer	1e-3	-9.040e+00	0.0072	17.0	24.64%
17		NPA82(bHLH)/Liver-NPA82-ChIP-Seq(GSE39860)/Homer	1e-3	-8.897e+00	0.0079	18.0	26.09%

## PCN

Rank	Motif	Name	P-value	log P-value	q-value (Benjamini)	# Target Sequences with Motif	% of Targets Sequences with Motif
1		RARa(NR)/K562-RARa-ChIP-Seq(Encode)/Homer	1e-11	-2.679e+01	0.0000	59.0	65.56%
2		CEBP(bZIP)/ThioMac-CEBPb-ChIP-Seq(GSE21512)/Homer	1e-9	-2.292e+01	0.0000	23.0	25.56%
3		CEBP-AP1(bZIP)/ThioMac-CEBPb-ChIP-Seq(GSE21512)/Homer	1e-9	-2.085e+01	0.0000	24.0	26.67%
4		Erra(NR)/HepG2-Erra-ChIP-Seq(GSE31477)/Homer	1e-7	-1.653e+01	0.0000	44.0	48.89%
5		THRB(NR)/Liver-NR1A2-ChIP-Seq(GSE52613)/Homer	1e-6	-1.580e+01	0.0000	62.0	68.89%
6		PPARa(NR),DR1/Liver-Ppar-ChIP-Seq(GSE47954)/Homer	1e-6	-1.479e+01	0.0001	27.0	30.00%
7		Atf4(bZIP)/MEF-Atf4-ChIP-Seq(GSE35681)/Homer	1e-5	-1.373e+01	0.0002	11.0	12.22%
8		COUP-TFII(NR)/K562-NR2F1-ChIP-Seq(Encode)/Homer	1e-5	-1.360e+01	0.0002	32.0	35.56%
9		HNf4a(NR),DR1/HepG2-HNF4a-ChIP-Seq(GSE25021)/Homer	1e-5	-1.360e+01	0.0002	17.0	18.89%
10		PPARb(NR),DR1/3T3L1-Pparg-ChIP-Seq(GSE13511)/Homer	1e-5	-1.287e+01	0.0003	24.0	26.67%
11		HLF(bZIP)/HSC-HLF-Flag-ChIP-Seq(GSE69817)/Homer	1e-5	-1.287e+01	0.0003	18.0	20.00%
12		Chop(bZIP)/MEF-Chop-ChIP-Seq(GSE35681)/Homer	1e-5	-1.214e+01	0.0004	9.0	10.00%
13		EAR2(NR)/K562-NR2F6-ChIP-Seq(Encode)/Homer	1e-5	-1.194e+01	0.0005	29.0	32.22%
14		FOXO1(Forkhead)/MCF7-FOXO1-ChIP-Seq(GSE72977)/Homer	1e-4	-1.130e+01	0.0009	21.0	23.33%
15		THRB(NR)/HepG2-THRB-Flag-ChIP-Seq(Encode)/Homer	1e-4	-1.118e+01	0.0009	16.0	17.78%
16		RXR(NR),DR1/3T3L1-RXR-ChIP-Seq(GSE13511)/Homer	1e-4	-1.117e+01	0.0009	23.0	27.78%
17		FOXA1(Forkhead)/MCF7-FOXA1-ChIP-Seq(GSE26831)/Homer	1e-4	-1.030e+01	0.0019	19.0	21.11%
18		VDR(NR),DR3/GM10855-VDR-vinD-ChIP-Seq(GSE22484)/Homer	1e-4	-9.571e+00	0.0038	9.0	10.00%
19		COUP-TFII(NR)/Artis-Nv2f2-ChIP-Seq(GSE46497)/Homer	1e-4	-9.334e+00	0.0045	31.0	34.44%
20		GRE(NR),IR3/RAW264.7-GRE-ChIP-Seq(Unpublished)/Homer	1e-4	-9.239e+00	0.0047	9.0	10.00%
21		bZIP28(bZIP)/col-bZIP28-DAP-Seq(GSE60143)/Homer	1e-3	-9.134e+00	0.0050	8.0	8.89%
22		FOXA1(Forkhead)/LNCAP-FOXA1-ChIP-Seq(GSE27824)/Homer	1e-3	-9.127e+00	0.0050	21.0	23.33%
23		Nr1a2(NR)/Pancreas-LRH1-ChIP-Seq(GSE34295)/Homer	1e-3	-8.987e+00	0.0053	18.0	20.00%
24		USF1(bHLH)/GM12878-USF1-ChIP-Seq(GSE32465)/Homer	1e-3	-8.812e+00	0.0061	12.0	13.33%
25		ABF1(bZIP)/Arabidopsis-ABF1-ChIP-Seq(GSE80564)/Homer	1e-3	-8.405e+00	0.0087	16.0	17.78%
26		THRB(NR)/C17.2-THRB-ChIP-Seq(GSE38347)/Homer	1e-3	-8.405e+00	0.0087	12.0	13.33%
27		NFIL3(bZIP)/HepG2-NFIL3-ChIP-Seq(Encode)/Homer	1e-3	-8.362e+00	0.0087	12.0	13.33%
28		ABF2(bZIP)/col-ABF2-DAP-Seq(GSE60143)/Homer	1e-3	-8.359e+00	0.0087	7.0	7.78%
29		AREB3(bZIP)/col-AREB3-DAP-Seq(GSE60143)/Homer	1e-3	-8.174e+00	0.0095	8.0	8.89%


Supplemental Figure 6. Examples of co-localization between PXR-binding and the epigenetic mark H3K4me2 around lncRNA gene loci

A



Green: PXR-DNA binding peaks;  
Purple: H3K4me2 peaks

B



Green: PXR-DNA binding peaks;  
Purple: H3K4me2 peaks



“-”: PCGs that were not expressed in liver

NCBI gene ID	NCBI gene locus	CO_1.FPM	CO_2.FPM	CO_3.FPM	TCPOB1.FPM	TCPOB2.FPM	TCPOB3.FPM	TCPOB4.FPM	TCPOB5.FPM	TCPOB6.FPM	TCPOB7.FPM	TCPOB8.FPM	TCPOB9.FPM	TCPOB10.FPM	TCPOB11.FPM	TCPOB12.FPM	TCPOB13.FPM	TCPOB14.FPM	TCPOB15.FPM	TCPOB16.FPM	TCPOB17.FPM	TCPOB18.FPM	TCPOB19.FPM	TCPOB20.FPM	TCPOB21.FPM	TCPOB22.FPM	TCPOB23.FPM	TCPOB24.FPM	TCPOB25.FPM	TCPOB26.FPM	TCPOB27.FPM	TCPOB28.FPM	TCPOB29.FPM	TCPOB30.FPM	TCPOB31.FPM	TCPOB32.FPM	TCPOB33.FPM	TCPOB34.FPM	TCPOB35.FPM	TCPOB36.FPM	TCPOB37.FPM	TCPOB38.FPM	TCPOB39.FPM	TCPOB40.FPM	TCPOB41.FPM	TCPOB42.FPM	TCPOB43.FPM	TCPOB44.FPM	TCPOB45.FPM	TCPOB46.FPM	TCPOB47.FPM	TCPOB48.FPM	TCPOB49.FPM	TCPOB50.FPM	TCPOB51.FPM	TCPOB52.FPM	TCPOB53.FPM	TCPOB54.FPM	TCPOB55.FPM	TCPOB56.FPM	TCPOB57.FPM	TCPOB58.FPM	TCPOB59.FPM	TCPOB60.FPM	TCPOB61.FPM	TCPOB62.FPM	TCPOB63.FPM	TCPOB64.FPM	TCPOB65.FPM	TCPOB66.FPM	TCPOB67.FPM	TCPOB68.FPM	TCPOB69.FPM	TCPOB70.FPM	TCPOB71.FPM	TCPOB72.FPM	TCPOB73.FPM	TCPOB74.FPM	TCPOB75.FPM	TCPOB76.FPM	TCPOB77.FPM	TCPOB78.FPM	TCPOB79.FPM	TCPOB80.FPM	TCPOB81.FPM	TCPOB82.FPM	TCPOB83.FPM	TCPOB84.FPM	TCPOB85.FPM	TCPOB86.FPM	TCPOB87.FPM	TCPOB88.FPM	TCPOB89.FPM	TCPOB90.FPM	TCPOB91.FPM	TCPOB92.FPM	TCPOB93.FPM	TCPOB94.FPM	TCPOB95.FPM	TCPOB96.FPM	TCPOB97.FPM	TCPOB98.FPM	TCPOB99.FPM	TCPOB100.FPM	TCPOB101.FPM	TCPOB102.FPM	TCPOB103.FPM	TCPOB104.FPM	TCPOB105.FPM	TCPOB106.FPM	TCPOB107.FPM	TCPOB108.FPM	TCPOB109.FPM	TCPOB110.FPM	TCPOB111.FPM	TCPOB112.FPM	TCPOB113.FPM	TCPOB114.FPM	TCPOB115.FPM	TCPOB116.FPM	TCPOB117.FPM	TCPOB118.FPM	TCPOB119.FPM	TCPOB120.FPM	TCPOB121.FPM	TCPOB122.FPM	TCPOB123.FPM	TCPOB124.FPM	TCPOB125.FPM	TCPOB126.FPM	TCPOB127.FPM	TCPOB128.FPM	TCPOB129.FPM	TCPOB130.FPM	TCPOB131.FPM	TCPOB132.FPM	TCPOB133.FPM	TCPOB134.FPM	TCPOB135.FPM	TCPOB136.FPM	TCPOB137.FPM	TCPOB138.FPM	TCPOB139.FPM	TCPOB140.FPM	TCPOB141.FPM	TCPOB142.FPM	TCPOB143.FPM	TCPOB144.FPM	TCPOB145.FPM	TCPOB146.FPM	TCPOB147.FPM	TCPOB148.FPM	TCPOB149.FPM	TCPOB150.FPM	TCPOB151.FPM	TCPOB152.FPM	TCPOB153.FPM	TCPOB154.FPM	TCPOB155.FPM	TCPOB156.FPM	TCPOB157.FPM	TCPOB158.FPM	TCPOB159.FPM	TCPOB160.FPM	TCPOB161.FPM	TCPOB162.FPM	TCPOB163.FPM	TCPOB164.FPM	TCPOB165.FPM	TCPOB166.FPM	TCPOB167.FPM	TCPOB168.FPM	TCPOB169.FPM	TCPOB170.FPM	TCPOB171.FPM	TCPOB172.FPM	TCPOB173.FPM	TCPOB174.FPM	TCPOB175.FPM	TCPOB176.FPM	TCPOB177.FPM	TCPOB178.FPM	TCPOB179.FPM	TCPOB180.FPM	TCPOB181.FPM	TCPOB182.FPM	TCPOB183.FPM	TCPOB184.FPM	TCPOB185.FPM	TCPOB186.FPM	TCPOB187.FPM	TCPOB188.FPM	TCPOB189.FPM	TCPOB190.FPM	TCPOB191.FPM	TCPOB192.FPM	TCPOB193.FPM	TCPOB194.FPM	TCPOB195.FPM	TCPOB196.FPM	TCPOB197.FPM	TCPOB198.FPM	TCPOB199.FPM	TCPOB200.FPM	TCPOB201.FPM	TCPOB202.FPM	TCPOB203.FPM	TCPOB204.FPM	TCPOB205.FPM	TCPOB206.FPM	TCPOB207.FPM	TCPOB208.FPM	TCPOB209.FPM	TCPOB210.FPM	TCPOB211.FPM	TCPOB212.FPM	TCPOB213.FPM	TCPOB214.FPM	TCPOB215.FPM	TCPOB216.FPM	TCPOB217.FPM	TCPOB218.FPM	TCPOB219.FPM	TCPOB220.FPM	TCPOB221.FPM	TCPOB222.FPM	TCPOB223.FPM	TCPOB224.FPM	TCPOB225.FPM	TCPOB226.FPM	TCPOB227.FPM	TCPOB228.FPM	TCPOB229.FPM	TCPOB230.FPM	TCPOB231.FPM	TCPOB232.FPM	TCPOB233.FPM	TCPOB234.FPM	TCPOB235.FPM	TCPOB236.FPM	TCPOB237.FPM	TCPOB238.FPM	TCPOB239.FPM	TCPOB240.FPM	TCPOB241.FPM	TCPOB242.FPM	TCPOB243.FPM	TCPOB244.FPM	TCPOB245.FPM	TCPOB246.FPM	TCPOB247.FPM	TCPOB248.FPM	TCPOB249.FPM	TCPOB250.FPM	TCPOB251.FPM	TCPOB252.FPM	TCPOB253.FPM	TCPOB254.FPM	TCPOB255.FPM	TCPOB256.FPM	TCPOB257.FPM	TCPOB258.FPM	TCPOB259.FPM	TCPOB260.FPM	TCPOB261.FPM	TCPOB262.FPM	TCPOB263.FPM	TCPOB264.FPM	TCPOB265.FPM	TCPOB266.FPM	TCPOB267.FPM	TCPOB268.FPM	TCPOB269.FPM	TCPOB270.FPM	TCPOB271.FPM	TCPOB272.FPM	TCPOB273.FPM	TCPOB274.FPM	TCPOB275.FPM	TCPOB276.FPM	TCPOB277.FPM	TCPOB278.FPM	TCPOB279.FPM	TCPOB280.FPM	TCPOB281.FPM	TCPOB282.FPM	TCPOB283.FPM	TCPOB284.FPM	TCPOB285.FPM	TCPOB286.FPM	TCPOB287.FPM	TCPOB288.FPM	TCPOB289.FPM	TCPOB290.FPM	TCPOB291.FPM	TCPOB292.FPM	TCPOB293.FPM	TCPOB294.FPM	TCPOB295.FPM	TCPOB296.FPM	TCPOB297.FPM	TCPOB298.FPM	TCPOB299.FPM	TCPOB300.FPM	TCPOB301.FPM	TCPOB302.FPM	TCPOB303.FPM	TCPOB304.FPM	TCPOB305.FPM	TCPOB306.FPM	TCPOB307.FPM	TCPOB308.FPM	TCPOB309.FPM	TCPOB310.FPM	TCPOB311.FPM	TCPOB312.FPM	TCPOB313.FPM	TCPOB314.FPM	TCPOB315.FPM	TCPOB316.FPM	TCPOB317.FPM	TCPOB318.FPM	TCPOB319.FPM	TCPOB320.FPM	TCPOB321.FPM	TCPOB322.FPM	TCPOB323.FPM	TCPOB324.FPM	TCPOB325.FPM	TCPOB326.FPM	TCPOB327.FPM	TCPOB328.FPM	TCPOB329.FPM	TCPOB330.FPM	TCPOB331.FPM	TCPOB332.FPM	TCPOB333.FPM	TCPOB334.FPM	TCPOB335.FPM	TCPOB336.FPM	TCPOB337.FPM	TCPOB338.FPM	TCPOB339.FPM	TCPOB340.FPM	TCPOB341.FPM	TCPOB342.FPM	TCPOB343.FPM	TCPOB344.FPM	TCPOB345.FPM	TCPOB346.FPM	TCPOB347.FPM	TCPOB348.FPM	TCPOB349.FPM	TCPOB350.FPM	TCPOB351.FPM	TCPOB352.FPM	TCPOB353.FPM	TCPOB354.FPM	TCPOB355.FPM	TCPOB356.FPM	TCPOB357.FPM	TCPOB358.FPM	TCPOB359.FPM	TCPOB360.FPM	TCPOB361.FPM	TCPOB362.FPM	TCPOB363.FPM	TCPOB364.FPM	TCPOB365.FPM	TCPOB366.FPM	TCPOB367.FPM	TCPOB368.FPM	TCPOB369.FPM	TCPOB370.FPM	TCPOB371.FPM	TCPOB372.FPM	TCPOB373.FPM	TCPOB374.FPM	TCPOB375.FPM	TCPOB376.FPM	TCPOB377.FPM	TCPOB378.FPM	TCPOB379.FPM	TCPOB380.FPM	TCPOB381.FPM	TCPOB382.FPM	TCPOB383.FPM	TCPOB384.FPM	TCPOB385.FPM	TCPOB386.FPM	TCPOB387.FPM	TCPOB388.FPM	TCPOB389.FPM	TCPOB390.FPM	TCPOB391.FPM	TCPOB392.FPM	TCPOB393.FPM	TCPOB394.FPM	TCPOB395.FPM	TCPOB396.FPM	TCPOB397.FPM	TCPOB398.FPM	TCPOB399.FPM	TCPOB400.FPM	TCPOB401.FPM	TCPOB402.FPM	TCPOB403.FPM	TCPOB404.FPM	TCPOB405.FPM	TCPOB406.FPM	TCPOB407.FPM	TCPOB408.FPM	TCPOB409.FPM	TCPOB410.FPM	TCPOB411.FPM	TCPOB412.FPM	TCPOB413.FPM	TCPOB414.FPM	TCPOB415.FPM	TCPOB416.FPM	TCPOB417.FPM	TCPOB418.FPM	TCPOB419.FPM	TCPOB420.FPM	TCPOB421.FPM	TCPOB422.FPM	TCPOB423.FPM	TCPOB424.FPM	TCPOB425.FPM	TCPOB426.FPM	TCPOB427.FPM	TCPOB428.FPM	TCPOB429.FPM	TCPOB430.FPM	TCPOB431.FPM	TCPOB432.FPM	TCPOB433.FPM	TCPOB434.FPM	TCPOB435.FPM	TCPOB436.FPM	TCPOB437.FPM	TCPOB438.FPM	TCPOB439.FPM	TCPOB440.FPM	TCPOB441.FPM	TCPOB442.FPM	TCPOB443.FPM	TCPOB444.FPM	TCPOB445.FPM	TCPOB446.FPM	TCPOB447.FPM	TCPOB448.FPM	TCPOB449.FPM	TCPOB450.FPM	TCPOB451.FPM	TCPOB452.FPM	TCPOB453.FPM	TCPOB454.FPM	TCPOB455.FPM	TCPOB456.FPM	TCPOB457.FPM	TCPOB458.FPM	TCPOB459.FPM	TCPOB460.FPM	TCPOB461.FPM	TCPOB462.FPM	TCPOB463.FPM	TCPOB464.FPM	TCPOB465.FPM	TCPOB466.FPM	TCPOB467.FPM	TCPOB468.FPM	TCPOB469.FPM	TCPOB470.FPM	TCPOB471.FPM	TCPOB472.FPM	TCPOB473.FPM	TCPOB474.FPM	TCPOB475.FPM	TCPOB476.FPM	TCPOB477.FPM	TCPOB478.FPM	TCPOB479.FPM	TCPOB480.FPM	TCPOB481.FPM	TCPOB482.FPM	TCPOB483.FPM	TCPOB484.FPM	TCPOB485.FPM	TCPOB486.FPM	TCPOB487.FPM	TCPOB488.FPM	TCPOB489.FPM	TCPOB490.FPM	TCPOB491.FPM	TCPOB492.FPM	TCPOB493.FPM	TCPOB494.FPM	TCPOB495.FPM	TCPOB496.FPM	TCPOB497.FPM	TCPOB498.FPM	TCPOB499.FPM	TCPOB500.FPM	TCPOB501.FPM	TCPOB502.FPM	TCPOB503.FPM	TCPOB504.FPM	TCPOB505.FPM	TCPOB506.FPM	TCPOB507.FPM	TCPOB508.FPM	TCPOB509.FPM	TCPOB510.FPM	TCPOB511.FPM	TCPOB512.FPM	TCPOB513.FPM	TCPOB514.FPM	TCPOB515.FPM	TCPOB516.FPM	TCPOB517.FPM	TCPOB518.FPM	TCPOB519.FPM	TCPOB520.FPM	TCPOB521.FPM	TCPOB522.FPM	TCPOB523.FPM	TCPOB524.FPM	TCPOB525.FPM	TCPOB526.FPM	TCPOB527.FPM	TCPOB528.FPM	TCPOB529.FPM	TCPOB530.FPM	TCPOB531.FPM	TCPOB532.FPM	TCPOB533.FPM	TCPOB534.FPM	TCPOB535.FPM	TCPOB536.FPM	TCPOB537.FPM	TCPOB538.FPM	TCPOB539.FPM	TCPOB540.FPM	TCPOB541.FPM	TCPOB542.FPM	TCPOB543.FPM	TCPOB544.FPM	TCPOB545.FPM	TCPOB546.FPM	TCPOB547.FPM	TCPOB548.FPM	TCPOB549.FPM	TCPOB550.FPM	TCPOB551.FPM	TCPOB552.FPM	TCPOB553.FPM	TCPOB554.FPM	TCPOB555.FPM	TCPOB556.FPM	TCPOB557.FPM	TCPOB558.FPM	TCPOB559.FPM	TCPOB560.FPM	TCPOB561.FPM	TCPOB562.FPM	TCPOB563.FPM	TCPOB564.FPM	TCPOB565.FPM	TCPOB566.FPM	TCPOB567.FPM	TCPOB568.FPM	TCPOB569.FPM	TCPOB570.FPM	TCPOB571.FPM	TCPOB572.FPM	TCPOB573.FPM	TCPOB574.FPM	TCPOB575.FPM	TCPOB576.FPM	TCPOB577.FPM	TCPOB578.FPM	TCPOB579.FPM	TCPOB580.FPM	TCPOB581.FPM	TCPOB582.FPM	TCPOB583.FPM	TCPOB584.FPM	TCPOB585.FPM	TCPOB586.FPM	TCPOB587.FPM	TCPOB588.FPM	TCPOB589.FPM	TCPOB590.FPM	TCPOB591.FPM	TCPOB592.FPM	TCPOB593.FPM	TCPOB594.FPM	TCPOB595.FPM	TCPOB596.FPM	TCPOB597.FPM	TCPOB598.FPM	TCPOB599.FPM	TCPOB600.FPM	TCPOB601.FPM	TCPOB602.FPM	TCPOB603.FPM	TCPOB604.FPM	TCPOB605.FPM	TCPOB606.FPM	TCPOB607.FPM	TCPOB608.FPM	TCPOB609.FPM	TCPOB610.FPM	TCPOB611.FPM	TCPOB612.FPM	TCPOB613.FPM	TCPOB614.FPM	TCPOB615.FPM	TCPOB616.FPM	TCPOB617.FPM	TCPOB618.FPM	TCPOB619.FPM	TCPOB620.FPM	TCPOB621.FPM	TCPOB622.FPM	TCPOB623.FPM	TCPOB624.FPM	TCPOB625.FPM	TCPOB626.FPM	TCPOB627.FPM	TCPOB628.FPM	TCPOB629.FPM	TCPOB630.FPM	TCPOB631.FPM	TCPOB632.FPM	TCPOB633.FPM	TCPOB634.FPM	TCPOB635.FPM	TCPOB636.FPM	TCPOB637.FPM	TCPOB638.FPM	TCPOB639.FPM	TCPOB640.FPM	TCPOB641.FPM	TCPOB642.FPM	TCPOB643.FPM	TCPOB644.FPM	TCPOB645.FPM	TCPOB646.FPM	TCPOB647.FPM	TCPOB648.FPM	TCPOB649.FPM	TCPOB650.FPM	TCPOB651.FPM	TCPOB652.FPM	TCPOB653.FPM	TCPOB654.FPM	TCPOB655.FPM	TCPOB656.FPM	TCPOB657.FPM	TCPOB658.FPM	TCPOB659.FPM	TCPOB660.FPM	TCPOB661.FPM	TCPOB662.FPM	TCPOB663.FPM	TCPOB664.FPM	TCPOB665.FPM	TCPOB666.FPM	TCPOB667.FPM	TCPOB668.FPM	TCPOB669.FPM	TCPOB670.FPM	TCPOB671.FPM	TCPOB672.FPM	TCPOB673.FPM	TCPOB674.FPM	TCPOB675.FPM	TCPOB676.FPM	TCPOB677.FPM	TCPOB678.FPM	TCPOB679.FPM	TCPOB680.FPM	TCPOB681.FPM	TCPOB682.FPM	TCPOB683.FPM	TCPOB684.FPM	TCPOB685.FPM	TCPOB686.FPM	TCPOB687.FPM	TCPOB688.FPM	TCPOB689.FPM	TCPOB690.FPM	TCPOB691.FPM	TCPOB692.FPM	TCPOB693.FPM	TCPOB694.FPM	TCPOB695.FPM	TCPOB696.FPM	TCPOB697.FPM	TCPOB698.FPM	TCPOB699.FPM	TCPOB700.FPM	TCPOB701.FPM	TCPOB702.FPM	TCPOB703.FPM	TCPOB704.FPM	TCPOB705.FPM	TCPOB706.FPM	TCPOB707.FPM	TCPOB708.FPM	TCPOB709.FPM	TCPOB710.FPM	TCPOB711.FPM	TCPOB712.FPM	TCPOB713.FPM	TCPOB714.FPM	TCPOB715.FPM	TCPOB716.FPM	TCPOB717.FPM	TCPOB718.FPM	TCPOB719.FPM	TCPOB720.FPM	TCPOB721.FPM	TCPOB722.FPM	TCPOB723.FPM	TCPOB724.FPM	TCPOB725.FPM	TCPOB726.FPM	TCPOB727.FPM	TCPOB728.FPM	TCPOB729.FPM	TCPOB730.FPM	TCPOB731.FPM	TCPOB732.FPM	TCPOB733.FPM	TCPOB734.FPM	TCPOB735.FPM	TCPOB736.FPM	TCPOB737.FPM	TCPOB738.FPM	TCPOB739.FPM	TCPOB740.FPM	TCPOB741.FPM	TCPOB742.FPM	TCPOB743.FPM	TCPOB744.FPM	TCPOB745.FPM	TCPOB746.FPM	TCPOB747.FPM	TCPOB748.FPM	TCPOB749.FPM	TCPOB750.FPM	TCPOB751.FPM	TCPOB752.FPM	TCPOB753.FPM	TCPOB754.FPM	TCPOB755.FPM	TCPOB756.FPM	TCPOB757.FPM	TCPOB758.FPM	TCPOB759.FPM	TCPOB760.FPM	TCPOB761.FPM	TCPOB762.FPM	TCPOB763.FPM	TCPOB764.FPM	TCPOB765.FPM	TCPOB766.FPM	TCPOB767.FPM	TCPOB768.FPM	TCPOB769.FPM	TCPOB770.FPM	TCPOB771.FPM	TCPOB772.FPM	TCPOB773.FPM	TCPOB774.FPM	TCPOB775.FPM	TCPOB776.FPM	TCPOB777.FPM	TCPOB778.FPM	TCPOB779.FPM	TCPOB780.FPM	TCPOB781.FPM	TCPOB782.FPM	TCPOB783.FPM	TCPOB784.FPM	TCPOB785.FPM	TCPOB786.FPM	TCPOB787.FPM	TCPOB788.FPM	TCPOB789.FPM	TCPOB790.FPM	TCPOB791.FPM	TCPOB792.FPM	TCPOB793.FPM	TCPOB794.FPM	TCPOB795.FPM	TCPOB796.FPM	TCPOB797.FPM	TCPOB798.FPM	TCPOB799.FPM	TCPOB800.FPM	TCPOB801.FPM	TCPOB802.FPM	TCPOB803.FPM	TCPOB804.FPM	TCPOB805.FPM	TCPOB806.FPM	TCPOB807.FPM	TCPOB808.FPM	TCPOB809.FPM	TCPOB810.FPM	TCPOB811.FPM	TCPOB812.FPM	TCPOB813.FPM	TCPOB814.FPM	TCPOB815.FPM	TCPOB816.FPM	TCPOB817.FPM	TCPOB818.FPM	TCPOB819.FPM	TCPOB820.FPM	TCPOB821.FPM	TCPOB822.FPM	TCPOB823.FPM	TCPOB824.FPM	TCPOB825.FPM	TCPOB826.FPM	TCPOB827.FPM	TCPOB828.FPM	TCPOB829.FPM	TCPOB830.FPM	TCPOB831.FPM	TCPOB832.FPM	TCPOB833.FPM	TCPOB834.FPM	TCPOB835.FPM	TCPOB836.FPM	TCPOB837.FPM	TCPOB838.FPM	TCPOB839.FPM	TCPOB840.FPM	TCPOB841.FPM	TCPOB842.FPM	TCPOB843.FPM	TCPOB844.FPM	TCPOB845.FPM	TCPOB846.FPM	TCPOB847.FPM	TCPOB848.FPM	TCPOB849.FPM	TCPOB850.FPM	TCPOB851.FPM	TCPOB852.FPM	TCPOB853.FPM	TCPOB854.FPM	TCPOB855.FPM	TCPOB856.FPM	TCPOB857.FPM	TCPOB858.FPM	TCPOB859.FPM	TCPOB860.FPM	TCPOB861.FPM	TCPOB862.FPM	TCPOB863.FPM	TCPOB864.FPM	TCPOB865.FPM	TCPOB866.FPM	TCPOB867.FPM	TCPOB868.FPM	TCPOB869.FPM	TCPOB870.FPM	TCPOB871.FPM	TCPOB872.FPM	TCPOB873.FPM	TCPOB874.FPM	TCPOB875.FPM	TCPOB876.FPM	TCPOB877.FPM	TCPOB878.FPM	TCPOB879.FPM	TCPOB880.FPM	TCPOB881.FPM	TCPOB882.FPM	TCPOB883.FPM	TCPOB884.FPM	TCPOB885.FPM	TCPOB886.FPM	TCPOB887.FPM	TCPOB888.FPM	TCPOB889.FPM	TCPOB890.FPM	TCPOB891.FPM	TCPOB892.FPM	TCPOB893.FPM	TCPOB894.FPM	TCPOB895.FPM	TCPOB896.FPM	TCPOB897.FPM	TCPOB898.FPM	TCPOB899.FPM	TCPOB900.FPM	TCPOB901.FPM	TCPOB902.FPM	TCPOB903.FPM	TCPOB904.FPM	TCPOB905.FPM	TCPOB906.FPM	TCPOB907.FPM	TCPOB908.FPM	TCPOB909.FPM	TCPOB910.FPM	TCPOB911.FPM	TCPOB912.FPM	TCPOB913.FPM	TCPOB914.FPM	TCPOB915.FPM	TCPOB916.FPM	TCPOB917.FPM	TCPOB918.FPM	TCPOB919.FPM	TCPOB920.FPM	TCPOB921.FPM	TCPOB922.FPM	TCPOB923.FPM	TCPOB924.FPM	TCPOB925.FPM	TCPOB926.FPM	TCPOB927.FPM	TCPOB928.FPM	TCPOB929.FPM	TCPOB930.FPM	TCPOB931.FPM	TCPOB932.FPM	TCPOB933.FPM	TCPOB934.FPM	TCPOB935.FPM	TCPOB936.FPM	TCPOB937.FPM	TCPOB938.FPM	TCPOB939.FPM	TCPOB940.FPM	TCPOB941.FPM	TCPOB942.FPM	TCPOB943.FPM	TCPOB944.FPM	TCPOB945.FPM	TCPOB946.FPM	TCPOB947.FPM	TCPOB948.FPM	TCPOB949.FPM	TCPOB950.FPM	TCPOB951.FPM	TCPOB952.FPM	TCPOB953.FPM	TCPOB954.FPM	TCPOB955.FPM	TCPOB956.FPM	TCPOB957.FPM
--------------	-----------------	----------	----------	----------	------------	------------	------------	------------	------------	------------	------------	------------	------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	-------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------	--------------



[illegible]

**Supplemental Table 3. Overlay between PXR-DNA binding and epigenetic marks around lncRNA gene loci on chromosomes 5, 12, and 15**

Epigenetic marks	# lncRNAs not expressed	# lncRNAs stably expressed	# lncRNAs increased by PCN	# lncRNAs decreased by PCN
H3K4me2	1680	174	9	13
H3K27me3	303	1	0	0
5MeC	1234	67	2	0
PXR	8257	753	45	70
PXR & H3K4me2	500	62	6	9
PXR & H3K27me3	11	0	0	0
PXR & 5MeC	121	9	0	0